Author: Editor

Allen Wilbanks stands at the forefront of SABCS 2023, the setting for a conversation with Thomas Budd, MD, a medical doctor and oncologist from the Cleveland Clinic Cancer Center. In this discussion, Allen introduces the focus—the Phase 1 trial of the Alpha-Lactalbumin vaccine in high-risk operable triple-negative breast cancer (TNBC) patients and those with a genetic predisposition to TNBC.Dr. Budd elaborates on the primary objectives of the trial, emphasizing the critical role of determining the appropriate vaccine dosage for future applications. The trial evaluates toxicity, primarily manifested as local injection site reactions, and measures immune responses through Alispot assays. The…

Allen Wilbanks finds himself at SABCS 2023, where he engages in a discussion with Dr. Adam Brufsky, a medical doctor, professor of medicine, and associate chief division hematology, oncology, and co-director of the Comprehensive Breast Cancer Center at the University of Pittsburgh.In the interview, Allen queries Dr. Brufsky about the real-world effectiveness of Palbociclib, or palbociclib, in combination with aromatase inhibitors for metastatic breast cancer patients with cardiovascular disease. Dr. Brufsky delves into the key findings of the study, highlighting the analysis of patients who were not part of clinical trials, and emphasizing the significance of real-world evidence.The study, known…

Wassim Mchayleh, MD, an expert in oncology, participated in the SABCS 2023 conference, offering insights into the latest developments in breast cancer research.Regarding groundbreaking findings or emerging trends at SABCS 2023, Dr. Mchayleh discussed studies potentially impacting clinical practices in breast cancer management, including novel therapeutic approaches and advancements in targeted therapies.In the area of cutting-edge technologies, Dr. Mchayleh addressed abstracts on precision medicine, genomics, and other innovative approaches in breast cancer research.The conversation then turned to a special feature on Minimal Residual Disease (MRD) testing. Dr. Mchayleh answered questions on the utility of MRD testing and its significance in…

Jeff Sharman, MD, a medical oncologist at the Willamette Ballet Cancer Institute and Research Center, also serving as the Medical Director of Hematology Research at the Sarah Cannon Research Institute.Phase 3 Elevate TN trial, a focus of Sharman’s work. The trial, designed for previously untreated chronic lymphocytic leukemia patients, included three arms: a control arm with Obinutuzumab chlorambucil, and two experimental arms with either acalabrutinib monotherapy or a combination of acalabrutinib with obinutuzumab. Sharman reveals that the study resulted in FDA approval for acalabrutinib in previously untreated patients.During the discussion, Sharman unveils key findings from the six-year follow-up study. Notably,…

Allen Wilbanks stood alongside Alina Hamilton, PhD, at the SABCS 2023 event, where they delved into groundbreaking research on breast cancer immunotherapy. Alina Hamilton, a postdoctoral research associate in the cancer control education program at the Lineberger Comprehensive Cancer Center, University of North Carolina Chapel Hill, shared insights on her work.Motivated by the alarming 41 percent higher breast cancer mortality rate among black women, Hamilton explored Survivin as a potential immunotherapy target. Survivin, a protein in the inhibitor of the apoptosis pathway, showed associations with aggressive tumor features, especially in breast cancer. Despite smaller and less diverse previous studies, Hamilton…

By: Melinda Telli, MD, Date: 12/9/2023 At the SABCS 2023 conference, we had the privilege of interviewing Melinda Telli, MD, a medical doctor, associate professor of medicine at Stanford University School of Medicine, and the director of the breast cancer program at Stanford Cancer Institute. Dr. Telli shared insights on recent advances in triple-negative breast cancer (TNBC) during a session she presided over.In the interview, Dr. Telli discussed progress in TNBC treatment and management, emphasizing that breakthroughs have occurred in the past five years. She traced the evolution of TNBC understanding since its first description in 2005, highlighting milestones such…

By: Hope Rugo, MD Date: 12/9/2023 At the SABCS 2023 conference, medical oncologist Hope Rugo from the University of California, San Francisco, engaged in a comprehensive discussion with interviewer Allen Wilbanks about the Keylink 009 study. Hope Rugo shared insights into the randomized open-label phase 2 trial, which aimed to assess the efficacy of the combination of Pembrolizumab and Olaparib as maintenance therapy for patients with triple-negative breast cancer (TNBC) receiving chemotherapy and Pembrolizumab.The trial enrolled patients with metastatic or locally advanced unresectable TNBC who had not undergone prior treatment in the metastatic setting. The treatment protocol involved induction chemotherapy…

By: Yara Abdou, MD, Date. 12/08/2023 At SABCS 2023, Yara Abdou, MD, a medical oncologist from the University of North Carolina Chapel Hill, discusses a phase one clinical trial titled “Translational Insights from a Phase One: First in Human Clinical Trial of the Anti-HER2.”In this trial, the focus is on CAR macrophages, a therapy for solid tumors expressing HER2, with 57 percent being breast cancer patients. Dr. Abdou explains the process: patients undergo leukophoresis to obtain monocytes, differentiated into macrophages, and transduced with an adenoviral vector to polarize the macrophage into an M1 phenotype. The CAR gene is encoded, and…

By: Hatem Azim, MD Date. 12/08/2023At SABCS 2023, a discussion on fertility preservation and assisted reproductive technologies in breast cancer patients interrupting endocrine therapy to attempt pregnancy. The speaker for this session was Hatem Azim, MD, a medical doctor, medical oncologist, and adjunct professor at the School of Medicine of the Monterey Institute of Technology. Additionally, Hatem Azim holds the position of Senior Oncology Faculty at the College of the European School of Oncology.Opening the conversation, Allen Wilbanks acknowledged Hatem Azim’s expertise and expressed gratitude for his presence in the discussion. Hatem Azim delved into the key findings from the positive trial…

Treatment differences by race and age in metastatic hormone receptor-positive/HER2- with Yara Abdour, MDTranscript (spelling not corrected)Yara Abdou, MD – Treatment differences by race and age in metastatic hormone receptor-positive/HER2- with Yara Abdour, MD 
Allen Wilbanks: [00:00:00] Okay, we’re here at S. A. B. C. S. 2023 and we’re lucky enough to have Dr Yara Abdu, a medical oncologist at the University of North Carolina Chapel Hill. Thank you so much for sitting down with us. 
Yara Abdou, MD: Absolutely. Thank you for having me. So 
Allen Wilbanks: today we’re gonna be discussing treatment differences by race and age and…

By: Julie Lang, MD Date. 12/07/2023Julie Lang, MD, a medical professional known for expertise in breast cancer research, has developed the Mechanical Conditioning Score (MCS), a test for identifying early-stage breast cancer patients with potential poor prognoses.The MCS evaluates mechanical factors and markers in breast tissues, such as tissue stiffness, cellular alignment, and extracellular matrix composition. It aids in predicting patient prognoses and informing treatment decisions.In terms of antifibrotic therapy, Lang’s research identifies how the MCS determines patients likely to respond to such interventions. By pinpointing individuals with increased tissue stiffness and fibrotic changes, the MCS becomes a tool for…

By. Terry Mamounas Date: 12/07/2023In a collaborative study between NVP and RT, led by oncologist Terry Mamounas, MD, the NSABP B-51/RTOG 1304 trial aimed to assess the role of local-regional radiotherapy in patients with initially positive axillary nodes that turned negative after neoadjuvant chemotherapy.The study objectives were to evaluate the necessity and potential benefits of local-regional radiotherapy in this specific patient population, focusing on the impact on invasive breast cancer recurrence-free interval (IBCF RFI). The study design incorporated a randomized comparison between patients receiving local-regional radiotherapy and those not, ensuring a thorough assessment of treatment effectiveness.Patient characteristics and demographics in…

By. Joanne Kotsopoulos, MD, Date: 12/07/2023 At the SABCS 2023 conference, Joanne Kotsopoulos, MD, a researcher from the Women’s College Research Institute in Toronto, engaged in a discussion with Allen Wilbanks. The focus of their conversation was on the cancer risk associated with exogenous hormone use in women with inherited BRCA1 or BRCA2 mutations, a topic Kotsopoulos has extensively researched.In her presentation, Kotsopoulos provided an overview of the complex relationship between exogenous hormones, such as oral contraceptives and hormone replacement therapy, and the risk of breast and ovarian cancer in mutation carriers. She delved into the existing evidence, including both established…

By: Virginia Kaklamani, MD Date: 12/8/2023 Virginia Kaklamani, MD, a professor of medicine in the Division of Hematology and Oncology at UT Health San Antonio and the leader of the breast cancer program at UT Health San Antonio MD Anderson Cancer Center, engaged in a conversation at SABCS 2023. Kaklamani shared insights on the highlights and trends observed during the event. Discussing various themes, the conference explored prevention strategies for breast cancer on chemopreventive strategies and estradiol level assessments to identify high-risk individuals. The discussions extended to advancements in early-stage treatment, exploring topics such as radiation therapy necessity and axillary…

By. Kellogg Parsons, MD Date: 12/07/2023 Kellogg Parsons, MD, a medical doctor and Vice President of Clinical Development at Embrace Therapeutics, joins him. As the interview unfolds, Dr. Parsons shares insights into the preclinical data of MBRC 101, a drug targeting the receptor tyrosine kinase.In their discussion, Dr. Parsons discusses the applications of MBRC 101 in advanced metastatic solid tumors, particularly in breast cancer subtypes like triple-negative and H.R. positive HER2-negative. The uniqueness of EphA5, highly expressed in cancer cells with minimal presence in normal tissues, makes it a prospect for targeted cancer therapy.Moving on to the pharmacokinetic aspects, Dr. Parsons…

By. Ruth O’Regan MD Date: 12/07/2023In an interview, Ruth O’Regan MD addresses questions related to the use of CDK4/6 inhibitors in the treatment of metastatic ER+ breast cancer. As an authority in the field, Dr. O’Regan provides perspectives on the ongoing debate regarding the similarities and differences among these inhibitors and their impact on patient outcomes.The first question explores the debate on whether CDK4/6 inhibitors exhibit distinct characteristics in terms of efficacy, given their known improvements in progression-free survival and overall survival. Dr. O’Regan discusses the nuances of this debate, providing an understanding of the variations among these inhibitors and their…

By. Neil Carleton, MD Date. 12/07/2023 In the interview with Neil Carleton, MD, the discussion revolved around the age-related remodeling of the systemic and breast microenvironment and its implications for promoting a tumor-permissive environment in ER+ breast cancer, as presented in recent research. Dr. Carleton expertly elaborated on the significance of factors beyond accumulating mutations, such as changes in estrogen disposition, inflammation, and immune contexture, in contributing to the age-related nature of ER+ breast cancer. He emphasized the potential impact of understanding these factors on future approaches to cancer prevention and treatment in older women.As the conversation delved deeper, Dr. Carleton…

By: Carol Fabian, MD Date. 12/07/2023 In an interview, Carol Fabian, MD, an expert in breast cancer research and prevention, will discuss critical aspects of breast cancer risk assessment and prevention. She will address the utility of polygenic risk scores, explaining how they complement imaging and influence decisions regarding risk reduction therapy.Dr. Fabian will provide information on hormone replacement and alternatives for women at moderate to high risk of developing breast cancer. She will discuss safe alternatives considered in this context, focusing on choices aligned with patient safety and well-being.The conversation will touch upon the presentation by Dr. Joanne Kotsopoulos, focusing…

By: Joyti Bajpai, MD Date: 12/07/2023 In a forthcoming interview, Jyoti Bajpai, MD, a renowned expert in the field, will explore the nuances of the Olanzapine-3 study, focusing on the comparison between low-dose and standard-dose Olanzapine in triple antiemetic therapy for highly emetogenic chemotherapy in solid tumor patients. Dr. Bajpai will provide insight into the significance of the Olanzapine study, shedding light on the impact of the combination therapy involving Olanzapine on complete response rates in patients undergoing highly emetogenic chemotherapy regimens. The interview will explore the potential breakthroughs this study presents for improving patient outcomes. The discussion will pivot…

By. Anjali Advani, MD Date. 12/06/2023 In this conversation on OncologyTube, viewers can explore the SWOG 18 clinical trial with host Allen Wilbanks and Dr. Anjali Advani, a medical oncologist and professor at the Cleveland Clinic. The discussion centers on the long-term follow-up data of combining dasatinib, prednisone, and blinatumomab for the treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) in older patients.Dr. Advani, the director of the inpatient leukemia program at the Cleveland Clinic, provides insights into the eligibility criteria for the study, specifically focusing on older patients with Ph+ ALL. The conversation delves into the treatment protocol’s…

By: Anjali Advani, MD Date: 12/06/2023 Dive into this insightful conversation with Dr. Anjali Advani, a distinguished medical oncologist and professor specializing in hemologic oncology and blood disorders at the Cleveland Clinic. Dr. Advani serves as the director of the inpatient leukemia program at the Tosset Cancer Institute. The discussion centers around groundbreaking research on Brexucabtagene Autoleucel therapy in adults with relapse refractory cells.Opening the conversation, Allen introduces Dr. Advani and expresses gratitude for her presence on the show. The dialogue delves into the significant response rates observed in adults treated with Brexucabtagene Autoleucel therapy. Dr. Advani emphasizes the real-world…

By. Fairooz F. Kabbinavar, MD, FACP​ Date. 12/06/2023 Fairooz F. Kabbinavar, MD, FACP, a medical oncologist with a background in academia and drug development, began his journey at Harvard in Boston, culminating in a hematology oncology fellowship at UCLA. During his 25-year tenure at UCLA, he rose to the rank of full professor of medicine and medical oncology, receiving an endowed chair for his contributions to clinical cancer research. Dr. Kabbinavar’s commitment to advancing cancer therapeutics, particularly in new drug development, led him to join Genentech and subsequently other biotech companies. His pivotal role in the development and approval of…

By. Josina Reddy, MDDate. 11/24/2023Today, the focus is on the ALINA trial, a phase three study comparing Alectinib versus chemotherapy as adjuvant therapy for patients with stage 1B to 3A ALK-positive non-small cell lung cancer. Presented in 2023, the trial results are discussed by Josina Reddy, MD. The significance of the phase 3 ALINA results lies in the 76% reduction in the risk of disease recurrence or death with Alectinib compared to platinum-based chemotherapy in ALK-positive early-stage non-small cell lung cancer.Josina Reddy, MD, explains that the ALINA trial enrolled patients with early-stage lung cancer that could be surgically removed, specifically…

By. Allen WilbanksDate. 11/23/2023Lot Aronson, MD, a medical doctor and researcher from the Department of Gynecologic Oncology in the Netherlands Cancer Institute, engaged in a discussion with Allen Wilbanks of Oncology Tube. The focus was the updated 10-year survival analysis from the OVHIPEC-1 trial, exploring the effects of cytoreductive surgery with or without hypothermic intraperitoneal chemotherapy (HIPEC) in patients with advanced ovarian cancer.Aronson initiated the conversation by providing an overview of the trial’s design, emphasizing its initiation in 2006 and subsequent publication in 2018. The OVHIPEC-1 trial, an open-label, randomized controlled phase three study, recruited patients from specialized centers in…

By. Anusha Kalbasi, MDDate. 11/22/2023In a recent discussion on adoptive T cell therapies for solid tumors, Anusha Kalbasi, MD, provided a comprehensive analysis of various modalities, shedding light on their challenges and potential breakthroughs. Kalbasi began by delving into the realm of tilt therapy, a longstanding approach for melanoma patients. Over the last decade or two, industry interest has surged, revealing response rates of 30 to 50 percent in heavily pretreated melanoma patients. The comparison with immune checkpoint blockade, particularly ipilimumab, has demonstrated promising data on tilt therapy’s longer progression-free survival.The conversation then shifted to TCR-engineered therapy, where Kalbasi elucidated…

By. Bridget Keenan, MDDate. 11/22/2023Bridget Keenan, MD, discusses the tumor microenvironment (TME) and its crucial role in cancer immunotherapy responses. Dr. Keenan notes that effector T cells align with positive outcomes, while suppressive myeloid cells and cytokine signals within the TME often signify a less favorable prognosis and resistance to immunotherapy.During the presentation, Dr. Keenan explores targeting the TME through immunotherapies, focusing on tumor metabolism and immunosuppressive myeloid cells. Despite various drugs aiming at the TME, no standout winner has emerged, prompting Dr. Keenan to discuss potential strategies for more effective interventions.She highlights exploring metabolic byproducts with higher concentrations in…

By. Bartosz Chmielowski, MD PhDDate: 11/22/2023In this presentation, Bartosz Chmielowski, MD PhD, discusses advancements in cancer therapy, focusing on approaches utilizing herpes virus-based treatments. The spotlight is on T VEC, the pioneering herpes virus therapy for cancer patients. The approval of this therapy was based on the durability of responses observed during clinical trials, demonstrating a heightened response rate compared to G-M-C-S-F injections alone.Bartosz Chmielowski, MD PhD, emphasizes the specificity of T VEC, clarifying that it is tailored for patients with easily injectable diseases, limited to skin lesions or palpable lymph nodes. The therapy showcased a borderline improvement in overall…

By. Anna M. Wu, MD, PhDDate. 11/21/2023Anna M. Wu, MD, PhD, discussed the use of immunotherapy in patients who underwent melanoma resection and reviewed drug development strategies in this field. She traced the progression from treating advanced, unresectable cases to improved outcomes in stage three and node-negative diseases.Wu highlighted the shift from post-surgery to pre-surgery immunotherapy, citing the S1801 clinical trial’s significant improvement in event-free survival with pre-surgery treatment. She discussed ongoing trials and emerging data on effective combinations, including early outcomes of a cancer vaccine in melanoma.Regarding the future of immunotherapy, Wu mentioned combining drugs like nivolumab and melatomab…

By. Arta Monjazeb, MDDate: 11/21/2023Arta Monir Monjazeb, MD, explores cancer immunotherapy with a detailed discussion on the immune response, radiation’s role, and the challenges of combining radiotherapy with immune checkpoint inhibitors (ICI). As a prominent figure in the field, Dr. Monjazeb brings forth insights that bridge clinical practice and research.In an exploration of the immune response, Dr. Monjazeb emphasizes the role of antigen-presenting cells in transitioning from innate to adaptive immunity. He discusses the intricate relationship between radiation and the immune system, emphasizing the importance of immunogenic cell death and the subsequent activation of T cells.Touching upon disparities among cancer…

By. Greg Daniels, MD Date: 11/21/2023 In this discussion, Dr. Greg Daniels, a physician in the field of solid organ transplantation, provides information on the complexities faced by transplant patients, particularly those who have undergone kidney or heart transplants. With experience, Dr. Daniels emphasizes the role of immune suppressive drugs in maintaining the viability of transplanted organs, preventing rejection by the recipient’s body.Dr. Daniels elucidates the various immune suppressive agents used, highlighting the differences among them. Notably, he underscores the risk of cancer, particularly skin cancers such as cutaneous squamous cell carcinoma, as a concern for transplant patients. The physician…

By. Katy Tsai, MDDate: 11/21/2023Katy Tsai, MD, discusses the progress in cancer survivorship on a national scale, citing data from the American Cancer Society projecting a significant increase in the number of cancer survivors in the United States over the next decade. Katy Tsai, specializing in treating advanced melanoma skin cancer patients, reflects on advancements in melanoma survivorship with the introduction of immune checkpoint inhibitors.In her dialogue, Katy Tsai delves into the historical context, emphasizing the shift from dire prognoses for metastatic melanoma patients to outcomes with contemporary treatments. She specifically mentions the success of combination immune checkpoint inhibitor blockade,…

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Stephen Liu gives an overview of treatment options for patients with NTRK+ NSCLC and what some side effects may be. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Stephen Liu discusses recent developments in RET+ NSCLC treatment, including next-generation RET TKIs. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Stephen Liu compares selpercatinib and pralsetinib as treatment options for patients with RET+ disease. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Stephen Liu discusses Pralsetinib as a treatment option for RET+ disease. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Stephen Liu discusses Selpercatinib as a treatment option for RET+ disease. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Stephen Liu discusses how RET fusions are detected, and discusses methods of treatment, including Selpercatinib and Pralsetinib. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Misako Nagasaka details treatment options and study data for patients with ROS1+ NSCLC. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Misako Nagasaka gives an in-depth discussion on ALK+ NSCLC, from possible treatment options to study data. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, the panel discusses the importance of knowing genetic testing results regardless of PD-L1 level. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, the panel discusses if there’s a reason some patients can remain on TKIs for extended time without developing resistance. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, the panel discusses methods of delivering SBRT, including CyberKnife. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, the panel discusses current understanding of what can cause lung cancer, and prevention methods. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, the panel discusses how patients can advocate for biomarker testing. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, the panel discusses local therapy options for patients with oligoprogression, and in particular, radiofrequency ablation for adrenal nodules. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, the panel discusses what a patient should discuss with their doctor if they progress on a targeted therapy. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, the panel discusses trial and treatment information for rare lung cancer mutations. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, the panel discusses the importance of biomarker testing even in early stage NSCLC. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, the panel discusses targeted therapy options for patients who have driver mutations. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, the panel discusses whether or not adding radiation will increase toxicity in patients who are already receiving targeted therapy. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, the panel discusses options for SBRT administration, and if treatment is affected if a patient is unable to hold their breath. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Puneeth Iyengar discusses local therapy options for patients with metastatic disease who have received a front-line therapy. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Puneeth Iyengar examines what has been learned from studies, what still remains unanswered, and future directions of local therapy treatments for patients with NSCLC. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Puneeth Iyengar discusses local therapy treatment options for patients who have oligoprogressive disease. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Puneeth Iyengar discusses the concept of using local therapy as an additional treatment for limited metastatic NSCLC, including Stereotactic Body Radiation Therapy (SBRT). For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and…

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Puneeth Iyengar discusses the concept of using local therapy as an additional treatment for limited metastatic NSCLC, including Stereotactic Body Radiation Therapy (SBRT). For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and…

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Puneeth Iyengar looks at current statistics for methods of adding to targeted therapy, as well as giving an overview of biology in treatment. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and…

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Joshua Reuss discusses what the patient can do to advocate for themselves during treatment. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Joshua Reuss discusses treatment options for patients with locally advanced NSCLC, and how to proceed while waiting for trial data. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Joshua Reuss discusses considerations and questions for targeted therapy before surgery. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Joshua Reuss explains why immunotherapy is not typically given to patients with resectable NSCLC and a driver mutation. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Joshua Reuss gives a brief description of the ongoing Alina trial for patients with ALK+ NSCLC. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Joshua Reuss gives a brief description of the ongoing Alina trial for patients with ALK+ NSCLC. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Joshua Reuss examines important details learned during the ADAURA trial, including overall survival, reduced risk of brain mets, and side effects. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Joshua Reuss discusses the ADAURA trial, which suggested Osimertinib as a treatment for EGFR+ NSCLC. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Aakash Desai discusses the administration of therapy for biomarkers, and how to overcome the gaps in administration, access, and affordability. For more, please visit http://cancerGRACE.org/. To watch the complete video click here: https://www.youtube.com/watch?v=v85bJi-vtGM&t=3939s BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE…

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Aakash Desai discusses how to address the issues of cost and insurance approval when obtaining biomarker testing. For more, please visit http://cancerGRACE.org/. To watch the full video click here: https://www.youtube.com/watch?v=ksZ6w3CEdPg BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Aakash Desai emphasizes the importance of physicians ordering biomarker testing for patients with NSCLC. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

By. Nicolas Rigard, MDDate. 11/20/2023In this interview, Nicolas Girard, MD, a medical doctor and professor of respiratory medicine at Versailles, St. Quentin University, and the head of the Curie-Montsouris Thorax Institute, discusses the PAPILLON study. The interview, conducted by Alan from OncologyTube, explores the comparison between Amivantamab plus chemotherapy and chemotherapy alone as the first-line treatment for EGFR Exon 20 insertion-mutated advanced non-small cell lung cancer.Nicolas Girard, MD, provides an overview of the study’s primary endpoint, progression-free survival (PFS), emphasizing the reduction in the risk of disease progression and the extension of median PFS with the Amivantamab plus chemotherapy combination.…

By. Kim Margolin, MDDate. 11/17/2023In the field of cancer immunotherapy, Kim Margolin, MD, provides insights into the interplay between the innate and adaptive immune systems. According to her, the innate immune system serves as a bridge, reacting swiftly against pathogens. This orchestration involves the secretion of cytokines, cytotoxic granules, and the engulfing of pathogens. Margolin emphasizes the concert between innate and adaptive immune responses, highlighting the significance of acute inflammation in anticancer reactions, in contrast to immunosuppression associated with chronic inflammation.Margolin delves into the field of tertiary lymphoid structures within tumors, elucidating their composition, which mirrors that of the adaptive…

By. Joaquim Bellmunt, MD, PhD Date. 11/17/2023 At the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain, Dr. Joaquim Bellmunt, MD, PhD, from Harvard Medical School in Boston, MA, shared insights on advancements in renal cancer during a dedicated session. Discussing first-line treatment options, Dr. Bellmunt highlighted the four established choices, including combinations of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors. In an interview, he touched upon the critical analysis of which patients are best suited for each treatment strategy. During the session, Dr. Bellmunt delved into the Phase III CONTACT-02 trial (NCT04446117) focusing on prostate…

By. Crispin Hiley, PhD Date. 11/17/2023 Crispin Hiley, PhD, from the UCL Cancer Institute in London, UK, discusses developments in second-line treatment for EGFR mutation-positive lung cancer patients at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain. Crispin Hiley, PhD, acknowledges progress in addressing the needs of patients who have progressed on osimertinib or third-generation tyrosine kinase inhibitors (TKIs). In an interview, Crispin Hiley, PhD, talks about studies on second-line EGFR mutation-positive lung cancer and the challenges faced by patients advancing on tyrosine kinase inhibitors. He acknowledges the existing unmet need, especially for those not suitable…

By. Mansoor Raza Mizra, MD Date. 11/16/2023 At ESMO this year, Mansoor Raza Mizra, MD, a figure in gynecologic oncology, shared insights on developments in the field. The focus began with cervical cancer, where three phase three randomized trials showed results. The Interlace trial, conducted in the neoadjuvant setting for locally advanced cervical cancer, demonstrated outcomes in both progression-free survival (PFS) and overall survival (OS). Another trial, exploring Cho radiation with or without pisab concomitant and maintenance in locally advanced cervical cancer, showed an increase in PFS, with a trend in OS, though data maturity is awaited. The third trial,…

By. Nicolas Girard, MD Date: 11/15/2023 In a significant development in the field of oncology, Nicolas Girard, MD, played a role in the approval of Amivantamab for the treatment of patients with advanced non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions. The approval specifically targets individuals who have experienced disease progression during or after platinum-based chemotherapy, representing an advancement in therapeutic options. The approval stems from a phase 3 international randomized trial overseen by Dr. Nicolas Girard and colleagues. In this trial, 308 patients with advanced NSCLC and EGFR exon 20 insertions, previously untreated with…

By: Allison Betof Warner, MD, PhD, StanfordDate: 11/13/2023 From: MOASCImmuno-Oncology Determining Optimal Treatment Duration Transcript: The question of how long to treat patients is one of the more challenging ones in our field. It’s always wonderful when our patients are responding. Classically in oncology, we kept patients on treatment indefinitely in the days of chemotherapy and even targeted therapy. Um, but we really feel that the immune system can learn to take care of a cancer itself from immunotherapy. And all of the data have suggested that over the years. the question is, how do we pick which patient is…

By. Aaron E. Lisberg, MD, Date. 11/14/2023 During ESMO 2023, Aaron E. Lisberg, MD, delivered a presentation on the results from the TROPION-Lung01 study, focusing on the clinical question of second-line chemotherapy for advanced metastatic non-small cell lung cancer compared to docetaxel. The study investigated a novel antibody-drug conjugate targeting TROPION-Lung01, Datopotamab deruxtecan, in a head-to-head comparison with docetaxel. Approximately 300 patients were enrolled and randomized at a one-to-one ratio, regardless of histology or the presence of targetable mutations. The trial had dual primary endpoints—progression-free survival (PFS) and overall survival (OS). Dr. Lisberg’s presentation concentrated on the PFS final analysis…

By. Filippo Pietrantonio, MD Date: 11/14/2023 Clinical data from the study demonstrated the inhibition of feedback reactivation pathways with an accumulation of activated GFR, providing a compelling rationale for combining Sotorasib with an anti-EGFR monoclonal antibody. Dr. Pietrantonio, MD, emphasized the need to enhance outcomes beyond monotherapy. The CodeBreak 300 trial, a global and phase 3 active-controlled open-label study, involved 160 patients randomized based on centrally confirmed KRAS G12C mutations after the failure of standard therapies. The trial featured three arms: Sotorasib at the standard dose (960 mg) plus panitumumab, Sotorasib at a lower dose (240 mg) plus panitumumab, and…

By. Peter Schmid, FRCP, MD, PhD Date. 10/11/2023 KEYNOTE-522 Phase 3 Results – Was Pembrolizumab a Win in Triple-Negative Breast Cancer? In this interview, Peter Schmid, FRCP, MD, PhD, from Barts Cancer Institute, London, UK, delves into the compelling 5-year follow-up data emanating from the Phase III KEYNOTE-522 (NCT03036488) trial. The trial was designed to investigate the efficacy of combining pembrolizumab with chemotherapy as neoadjuvant therapy and pembrolizumab as adjuvant therapy in patients grappling with the challenges of triple-negative breast cancer. The previously reported findings from the trial had already indicated noteworthy and statistically significant improvements in both pathological complete…

By. Funda Meric-Bernstam, MD Date. 10/11/2023 LBA34 – Trastuzumab deruxtecan (T-DXd) for pretreated patients with HER2-expressing solid tumors. Professor Funda Meric-Bernstam presented pivotal findings at the ESMO Congress 2023, shedding light on the latest developments in the realm of cancer treatment. The focal point of her presentation was the noteworthy LBA34 – Trastuzumab deruxtecan (T-DXd) for HER2-expressing solid tumors. These insights emanated from the primary analysis of the DESTINY-PanTumor02 (DP-02) study, offering a comprehensive examination of T-DXd’s efficacy in a diverse cohort of patients. The study, designed to address the therapeutic potential of T-DXd, specifically targeted patients with HER2 expression…

By. Yennifer Chan, MD Lisa Yen, MD Courtesy: LACNETS Date. 11/09/2023 Cabozantinib in the CABINET Trial: NET Results Lisa Yen, MD, the Director of Programs and Outreach at ESMO 2023 in Madrid, is alongside Dr. Jennifer Chan, the Principal Investigator of the Alliance Phase Three Study. This study, known as the Cabinet Study, explores Cabozantinib’s efficacy compared to a placebo in Advanced Neuroendocrine Tumors after prior therapy. Dr. Chan recently revealed the trial’s outcomes, demonstrating the effectiveness of Cabozantinib in both cohorts of patients. The results showed an improvement in progression-free survival for those receiving Cabozantinib compared…

By: Dr. Rahul Gusain, MD Dr. Rohit Gusain, MD Dr. Joshua Reuss, MD Date: 11/07/2023 Courtesy: OncologyBrothers Drs. Rahul Gosain, MD and Rohit Gosain, MD, referred to as the oncology brothers, reflected on the impressive content presented at ESMO 2023. They segmented the lung cancer highlights into two key studies: KEYNOTE 671 focusing on resectable non-small cell lung cancer and the Alina trial for ALK-positive patients. They were joined by Dr. Joshua Reuss from Georgetown Lombardi Kansas Center. KEYNOTE 671 Results from ESMO 2023 KEYNOTE 671, a phase 3 study, examined the peroperative IO…

The full video from the Spanish Targeted Therapies in Lung Cancer Patient Forum 2023 is available now to view ONDemand, while we edit and produce smaller videos by topic. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Aakash Desai discusses the current recommendations for biomarker testing in patients with NSCLC, as well as best practices. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Aakash Desai gives a basic overview of biomarkers and discusses which ones are important for patients with NSCLC. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Aakash Desai details the importance of biomarker testing and discusses the method of liquid biopsy to do so. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

This full unedited version of the 2023 Targeted Therapies in Lung Cancer Patient Forum presentations from the Mainstage, on Saturday, July 15, 2023 is now available OnDemand. These topics will be edited and offered as shorter videos in the coming weeks. For the breakout presentations from the 2nd Stage, please see: https://youtu.be/XITX_YhElIE For more, please visit http://cancerGRACE.org/. To ask a question, visit https://cancergrace.org/forum.

This full unedited version of the 2023 Targeted Therapies in Lung Cancer Patient Forum presentations from the Mainstage, on Saturday, July 15, 2023 is now available OnDemand. These topics will be edited and offered as shorter videos in the coming weeks. For the full mainstage presentations please see: https://youtu.be/v85bJi-vtGM For more, please visit http://cancerGRACE.org/. To ask a question, visit https://cancergrace.org/forum.

By: Byoung Chul Cho, MD, PhD, Yonsei University, Seoul, Korea, Date: 11/03/2023 Courtesy: VJOncology Above is a video from Byoung Chul Cho, MD, PhD, Yonsei University, Seoul, Korea about the MARIPOSA Phase 3 trial a randomized study comparing amivantamab plus lazertinib compared to osimertinib in advanced EGFR mutated lung cancer. During this ESMO 2023, the primary and some secondary endpoints of the MARIPOSA study were presented. The primary endpoint of the MARIPOSA study aimed to evaluate the progression-free survival (PFS) of amivantamab plus lazertinib compared to osimertinib according to RECIST version 1.1. The secondary endpoints included overall survival, duration of…

By. Stuart McIntosh, MDDate. November 03, 2023Stuart McIntosh, MD, Chief Medical Officer, initiated a study in the field of oncology. His work involved combining samuraciclib, a CDK7 inhibitor, with elacestrant, an oral Selective Estrogen Receptor Degrader (SERD), specifically for patients with CDK4/6 inhibitor-resistant HR+, HER2- metastatic breast cancer.The study aimed to address resistance to CDK4/6 inhibitors in this specific patient subset. McIntosh’s research sought to explore the benefits of this combination therapy, focusing on efficacy, safety, and tolerability.The investigation explored the risks and benefits linked with the combination therapy. Early findings indicated potential therapeutic advantages in managing resistance in this…

By. Mohammed Dar, MDDate. November 02, 2023Mohammed Dar, MD, observed significant advancements in the treatment of metastatic uveal melanoma, particularly for HLA-A02:01 positive patients with the introduction of tebentafusp (TA BENT A FUSP). In comparison to the control group, tebentafusp demonstrated notable improvements in overall survival rates. The specific data revealed a substantial increase in survival rates among patients receiving tebentafusp compared to those in the control group. This has a significant impact on the current standard of care for HLA-A02:01 positive patients, potentially reshaping treatment protocols for this subgroup.Regarding early survival benefits, the first six weeks of tebentafusp treatment…

By. Corina Dutcus, MDDate. November 02, 2023Corina Dutcus, MD, a lead investigator in the Phase 3 LEAP-014 trial for metastatic esophageal squamous cell carcinoma, presented insights into the trial’s objectives, findings, and implications for patient care.The Phase 3 LEAP-014 trial aimed to evaluate the efficacy and safety of combining lenvatinib, pembrolizumab, and chemotherapy for this cancer type, focusing on overall survival, progression-free survival, and safety measures.Dr. Dutcus summarized the trial findings, noting improvements in overall survival, progression-free survival, and a manageable safety profile for the combination therapy.The addition of lenvatinib and pembrolizumab to chemotherapy represents a significant advancement in the…

By. Tyler Ames, PhDDate. November 01, 2023Tyler Ames, Ph.D. in oncology research, delves into the intricate mechanisms of PT-112’s impact on cancer cells and its potential significance in treating metastatic castration-resistant prostate cancer and thoracic malignancies.Addressing the significance of PT-112’s ability to release damage-associated molecular patterns (DAMPs) and induce immunogenic cell death (ICD), Dr. Ames underscores their pivotal role in the immune system’s response against cancer. The release of DAMPs triggers an immune response, alerting the body to recognize and target cancerous cells, particularly crucial in metastatic and castration-resistant prostate cancer and thoracic malignancies.When exploring the early molecular effects of…

By. Aditya Bardia, MDDate. November 01, 2023 Dr. Aditya Bardia, an oncologist specializing in breast cancer treatment, provided insights into the NATALEE trial, presenting pivotal data at ESMO 2023. The trial, under his leadership, aimed to advance breast cancer therapy and contribute significantly to understanding treatment modalities. Dr. Bardia’s contributions to the trial and subsequent findings established him as a prominent figure in advancing breast cancer research. The NATALEE trial had specific objectives, focusing on improving outcomes for patients with HER2-positive early breast cancer. It investigated the effectiveness of dual HER2 blockade (using two anti-HER2 agents) in combination with chemotherapy…

By. Corina Dutcus, MDDate. November 01, 2023Corina Ductus, MD, a medical doctor and the Senior Vice President of Clinical Development at Eisai, recently addressed critical aspects of the Phase 3 Study 309/KEYNOTE-775 trial focusing on patients with advanced endometrial cancer. The trial specifically evaluated the efficacy of pembrolizumab in combination with lenvatinib for patients who had undergone prior platinum therapy.During the interview, Dr. Ductus discussed the key findings from the trial. The research showcased significant improvements in progression-free survival (PFS), overall survival (OS), and objective response rate (ORR). These statistically and clinically significant enhancements in patient outcomes hold immense significance…

Author: Dr Antonio Passaro (on-camera comments) – Courtesy of ESMO.org At the ESMO 2023 conference, the results of the Phase three global randomized Mariposa 2 trial were presented. The trial focused on patients with advanced non-small cell lung cancer after progressing on Ozimertinib due to an EGFR mutation. The study aimed to evaluate Amivantamab combined with chemotherapy, with or without Lazertinib, compared to standard chemotherapy. The trial involved 657 patients from various regions and aimed to assess progression-free survival. The primary endpoint was to compare the survival benefits among the different treatment arms. The study found a statistically significant improvement in…

Author: Dr. Yelena Janjigian (on-camera comments) – Courtesy of ESMO.org The Matterhorn study, a significant phase three global research effort, aims to determine the efficacy of a triplet regimen involving chemotherapy with flood alongside durvalumab in treating early-stage non-metastatic gastric and gastroesophageal adenocarcinoma. Presented at ESMO 2023, the study’s first interim analysis involved nearly 1000 patients from various regions globally, utilizing a randomized approach of flood plus durvalumab or placebo. Results revealed a 12% enhancement in complete response rate and a 15% improvement in node negativity status, which is crucial for clinical outcomes. While the study successfully met its interim…

By. Antonio Passaro, MDDate. October 31, 2023Antonio Passaro, MD, an oncologist specializing in lung cancer, has been deeply involved in the analysis and interpretation of the Phase 3 MARIPOSA-2 study. The primary objective of this pivotal trial was to investigate the efficacy and safety of the amivantamab regimen, in combination with chemotherapy, for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring specific EGFR mutations.The study’s key findings have been groundbreaking, revealing a significant advancement in the treatment landscape for NSCLC. Dr. Passaro highlights the remarkable results that demonstrate a 56% and 52% reduction in the risk…

By. Noura Choudhury, MD Date. October 31, 2023Noura Choudhury, MD, a medical researcher specializing in oncology therapeutics, is a key figure in understanding the clinical significance of HPN328, a cutting-edge immunotherapy drug. Her expertise and experience in the field enable a comprehensive analysis of recent clinical trial data and its implications for cancer treatment.In the interview, Dr. Noura Choudhury addresses the significant insights drawn from HPN328’s clinical trial results. Highlighting the drug’s remarkable confirmed response rate of 35% across diverse tumor types with a mere 1 mg priming dose, including instances of complete responses, she elucidates the potential implications for…

By. Mohamed H. Derbala, MDDate. October 31, 2023Mohamed H. Derbala, MD, an immuno-oncology expert and a Research Scientist at MD Anderson Cancer Center, is slated to share his expertise during an exclusive interview. The discussion will revolve around pivotal inquiries concerning TIGIT and its implications in immunotherapy.The interview will provide a comprehensive exploration of various critical facets related to TIGIT. Dr. Derbala will delve into the intricate role that TIGIT plays in immune suppression, shedding light on its function as an inhibitory receptor impacting immune cells such as T cells and natural killer (NK) cells. His extensive research and findings…

By. Corina Dutcus, MDDate. October 30, 2023In this video interview, Corina Dutcus, MD, will address pivotal aspects of phase 3 CLEAR study, focusing on the combination of lenvatinib and pembrolizumab in the treatment of advanced clear cell renal cell carcinoma (ccRCC). She will dive into the key findings and their implications for clinical practice.Dr. Dutcus will highlight the study’s pivotal results, emphasizing the better objective response rate (ORR) achieved with the lenvatinib and pembrolizumab combination compared to sunitinib. She will explain the significance of ORR in this context, elucidating its role as a metric in evaluating treatment efficacy.Furthermore, the discussion…

Author: Dr Michiel van der Heijden (on-camera comments) – Courtesy of ESMO.org Checkmate 901, a study focusing on first-line treatment for metastatic or irresectable urothelial cancer patients, aimed to improve existing chemotherapy approaches. Traditionally, chemotherapy, primarily cisplatin or gemcitabine, has been the standard for such cases. With the recent introduction of immunotherapy, there has been a challenge as many patients were unable to transition to immunotherapy post-chemotherapy. Involving around 600 patients, the study randomized participants into two groups: one receiving the standard cisplatin-gemcitabine and the other receiving this combination along with nivolumab, a checkpoint inhibitor. The trial successfully met its…

Dr Laurence Albiges (on-camera comments) – Courtesy of ESMO.org During ESMO 2023, an individual presented a study at the forefront of oncology research. The study, known as LITESPARK-005, focused on patients with advanced kidney cancer who had previously undergone unsuccessful therapy. The trial explored the effectiveness of Belzutifan, a first-in-class inhibitor, in treating clear cell renal cell carcinoma (RCC) by targeting the hypoxia-inducible factor. This inhibitor, Belzutifan, works by impeding the dimerization of IF 2A, thereby blocking the downstream oncogenic pathway. The study enrolled over 700 patients and demonstrated positive outcomes. Primary results showed a significant increase in progression-free survival…

Author: Dr Herbert Ho Fung Loong (on-camera comments) – Courtesy of ESMO.org During ESMO 2023, I’ve had the pleasure of presenting our groups data which is the Libretto 431 study which is actually a first line study of the use of supper catching it versus standard chemotherapy plus pembrolizumab in patients with newly diagnosed red fusion positive non small cell lung cancer. So by way of background red fusion accounts for about 2% of all non small cell lung cancers. And previously at least prior to the knowledge of knowing the fact that RET as a driver for most of these…

Author: Dr. Oliver Sartor (on-camera comments) – Courtesy of ESMO.org At ESMO 2023, an opportunity arose to present new data from the [177Lu]Lu-PSMA-617 trial, which focused on metastatic KR-resistant prostate cancer in treatment-naive patients. The study compared two agents from different classes: IS lithium and a secondary hormone (either abiraterone or insulin). Eligibility for the study was determined through PSMA PET scans, which revealed that 92% of patients were qualified. A total of 468 patients were randomized, with the primary endpoint being radiographic progression-free survival (rpfs). The data presented at ESMO showed a significantly positive outcome, with an rpfs Hazard…

Author: Professor Ben Solomon (on-camera comments) – Courtesy of ESMO.org At ESMO 2023, the speaker had the pleasure of presenting the findings from the global phase 3 Alina study. This study marked the first randomized investigation of aninhibitor in patients with entirely resected ALK-positive non-small cell lung cancer. The presentation highlighted the high recurrence rates after surgery in this patient population and emphasized that the advances seen in early-stage immunotherapy didn’t apply here. The standard of care still revolved around Adan Platinum-based chemotherapy. In the Alina study, the effects of two years of LBA2 – ALINA treatment on disease-free survival after…

Author: Dr. Domenica Lorusso (on-camera comments) – Courtesy of ESMO.org During ESMO 2023, the results of the ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial were presented. This trial marked the first evaluation of Pembrolizumab immunotherapy in combination with chemoradiation for locally advanced high-risk cervical cancer since 1999. Historically, the treatment for such patients involved concomitant chemoradiation followed by brachytherapy. However, this trial aimed to demonstrate an improvement in progression-free and overall survival when combining immunotherapy with chemoradiation. A total of 160 patients were enrolled and randomized into two groups: one receiving concomitant chemoradiation followed by brachytherapy with a placebo, and the other receiving the same…

By. Shannon Westin, MDDate. October 27, 2023In the video interview, Shannon Westin, MD, discusses the key findings from the DUO-E Phase III trial, focusing on the combination of IMFINZI® (durvalumab) and LYNPARZA® (olaparib) in advanced or recurrent endometrial cancer and its implications for patient treatment options.Dr. Shannon Westin highlights the significant impact of the DUO-E Phase III trial findings on the management of advanced or recurrent endometrial cancer. She emphasizes that the combination of IMFINZI® and LYNPARZA® showed a remarkable 45% reduction in the risk of disease progression or death when compared to chemotherapy in the overall trial population. This…

By. Brian SlomovitzDate. October 26, 2023 Brian Slomovitz, MD, presented insights into the innovaTV 301 study and its implications for patients dealing with the condition. Within the innovaTV 301 study, crucial findings emerged for cervical cancer patients, showcasing advancements in overall survival, progression-free survival, and objective response rate. These outcomes held significant value for the patients. Specifically, the study highlighted how tisotumab vedotin (TV) extended both the overall and progression-free survival compared to standard chemotherapy. This meant an extended life expectancy and delayed disease progression for patients treated with TV. While the objective response rate was lower than observed in…

By. Neil Gross, MDDate. October 26, 2023 In a discussion detailing the primary outcomes of the Phase 2 trial for Libtayo as a neoadjuvant therapy for Cutaneous Squamous Cell Carcinoma (CSCC), Dr. Neil Gross presented critical aspects related to the study. The trial, incorporating the use of Libtayo, a PD-1 inhibitor developed by Regeneron Pharmaceuticals, Inc., aimed to assess its effectiveness as a neoadjuvant monotherapy in stage II to IV resectable CSCC. This trial marked a significant milestone in oncology and was showcased at the European Society for Medical Oncology (ESMO) Congress 2023 and concurrently published in The Lancet Oncology.…

By: Neal Shore, MD Date: October 25, 2023 In the abstract describing the EMBARK Phase 3 trial, Dr. Neal Shore serves as a key figure in elucidating the trial’s primary objective. The primary aim of this clinical trial is to assess the safety and efficacy of the combination therapy involving enzalutamide and leuprolide in patients with high-risk biochemical recurrence of prostate cancer.The patient group identified as “high-risk for biochemical recurrence” in this trial comprises individuals who have previously undergone primary treatment for prostate cancer and subsequently experienced a rise in prostate-specific antigen (PSA) levels. These patients are at greater risk…

By: Loren Michel, MD Date: October 25, 2023 At the recent ESMO conference, Dr. Loren Michel presented the results of the TROPiCS-03 clinical trial, which investigated the use of sacituzumab govitecan (SG) in advanced head and neck cancer. The primary and key secondary endpoints in this study held significant importance in assessing SG’s effectiveness in patients with advanced HNSCC. The primary endpoint was the objective response rate (ORR), which stood at 16%. The ORR represents the proportion of patients who exhibited a meaningful tumor response to SG, indicating its potential to shrink or stabilize tumors. The key secondary endpoint, the…

By: Thomas Powles, MD Date: October 25, 2023 An exclusive interview occurred with Dr. Thomas Powles, MD, the lead investigator of the EV-302 phase 3 trial, where the discussion revolved around the Enfortumab Vedotin and Pembrolizumab combination and its potential impact on bladder cancer treatment. During the interview, Dr. Powles detailed how the Enfortumab Vedotin-Pembrolizumab combination displayed a 53% reduction in the risk of death in comparison to conventional chemotherapy for bladder cancer patients. The conversation explored the factors contributing to the extended median overall survival of 31.5 months for patients on the combination regimen, a significant improvement over the…

By. Katja Weisel, MD Date: October 25. 2023 In the world of multiple myeloma research, Dr. Katja Weisel, MD, stands at the forefront of groundbreaking clinical trials. Her work on the GMMG-CONCEPT trial, involving Isatuximab combination therapy, has unveiled a pivotal shift in the treatment landscape for high-risk multiple myeloma patients. Achieving sustained minimal residual disease (MRD) negativity is a remarkable feat in the context of this complex blood cancer. MRD negativity implies that there is an exceedingly low level of cancer cells remaining in a patient’s system. In high-risk multiple myeloma, the significance of this achievement cannot be overstated.…

By: Abdulraheem Yacoub MD Date: October 25, 2023 In a prestigious medical conference hall filled with experts in the field of hematological cancers, Abdulraheem Yacoub MD took the stage to address the attentive audience. He commenced his speech with gratitude, saying, “Thank you, Lucia. It’s my pleasure now to invite Abia Kube, who runs what I call an MPN Empire in the middle of the country, and is leading the Limber phase three study in the front line and has also done some great work with the consortium. Thanks, Abe. Good afternoon.” Dr. Yacoub’s appreciation extended further as he continued, acknowledging the…

By: Elizabeth Brem, MD Date: October 06, 2023 Elizabeth Brem, MD, began her talk by addressing some disclosures she had omitted in her previous presentation. She then stressed the importance of intergroup studies, particularly for rare populations like PTCL and HL. She highlighted their unique ability to establish real comparator arms, citing examples from CLL trials. Moving on to specific studies, Dr. Brem emphasized the groundbreaking nature of “eighteen twenty six” in Hodgkin lymphoma, describing it as a study poised to change the standard of care in a way that no other mechanism could achieve. She also discussed the potential…

By: John Mascarenhas, MD Date: October 04, 2023 John Mascarenhas, MD, stands as a distinguished authority in the realm of myelofibrosis treatment. Drawing upon his extensive expertise and experience, Dr. Mascarenhas delivered an enlightening presentation in 2023, shedding light on the drugs Pacritinib and Mamelotnib. During his presentation, he underscored the critical importance of comprehending the distinct properties and profiles of these two JAK inhibitors. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023…

By: Allen Wilbanks Date: October 03, 2023 Julie Vose, MD, a respected expert in the field of lymphoma, began her presentation by acknowledging the challenging nature of mantle cell lymphoma and introduced herself with the following quote: “Thank you very much. So it’s my pleasure to talk about mantle cell lymphoma, another challenging lymphoma. These are my disclosures.” She went on to provide valuable insights into mantle cell lymphoma, emphasizing its prevalence, gender distribution, and the often advanced stage at which patients are diagnosed. Julie stated, “Mantle cell lymphoma, not the most common lymphoma, about sixty nine percent, and patients…

Preventing a Carboplatin Shortage: Strategies to Ensure Cancer Drug Availability in 2023 In an era where advancements in cancer treatment are making great strides, the looming threat of a carboplatin shortage casts a shadow over these achievements. Carboplatin, a critical chemotherapy drug, is essential for treating various forms of cancer. However, recent shortages have disrupted patient care and left healthcare providers scrambling for solutions. What are the consequences of these carboplatin shortages, and how can we address them to ensure that cancer patients receive the life-saving treatments they need? Key Takeaways Carboplatin shortage has caused disruptions in cancer treatment, necessitating…

Harnessing the Power of Dostarlimab to Treat Advanced or Recurrent Endometrial Cancer Endometrial cancer remains a significant challenge for medical oncology. However, recent advances in cancer treatment have brought a new hope for patients with advanced or recurrent endometrial cancer: Dostarlimab. How does this innovative immunotherapy work, and what does it mean for patients with this challenging disease? Read on to discover the breakthroughs of the RUBY trial and the potential impact of Dostarlimab on endometrial cancer treatment. Key Takeaways Dostarlimab (Jemperli) is an innovative immunotherapy approved by the FDA for advanced or recurrent endometrial cancer. The RUBY trial revealed…

GeoVax, a pioneering healthcare company, has developed a groundbreaking product known as GADEPTIN. GADEPTIN is a cutting-edge therapy designed to target and treat the initial indications of advanced head and neck cancer, with the potential to address various solid tumors as well. The mechanism behind this innovative treatment involves the use of an enzyme, the PNP enzyme, which is delivered into the tumor through an established adenovirus vaccine.The treatment process begins by administering the PNP enzyme directly into the targeted tumor. Most tumors are accessible with a needle, making this a precise and localized delivery method. Following the introduction of…

By: Allen WilbanksDate: October 01, 2023 In a conference room filled with medical professionals and researchers, the audience leaned forward, eager to hear the insights of the esteemed Raajit Rampal, MD. As he took the stage, he couldn’t help but make a light-hearted comment about the outdated slides he was presented with. “That’s an outdated slide,” Dr. Rampal remarked with a chuckle. “The Abe is now a full professor.” His comment drew a few laughs from the audience, setting a relaxed tone for the presentation. Dr. Rampal then introduced his collaborator, Doctor Ramal, with warm praise. “And now from the…

By: Allen WilbanksDate: October 02, 2023 In a comprehensive discussion led by the esteemed Swami Lyer, MD, the focus centered on the evolving landscape of therapies for T-cell lymphomas. Dr. Lyer commenced the talk with expressions of gratitude, acknowledging the invaluable contributions of patients participating in clinical studies. The central theme revolved around elucidating the prospects of late and forthcoming treatments in T cell lymphomas, with an emphasis on the pivotal role of transplantation. One of the primary challenges in managing T cell lymphomas is the intricate classification system. Dr. Lyer illustrated the complexity by highlighting the multitude of subtypes…

By: Allen Wilbanks Date: September 29, 2023 In the groundbreaking Phase 3 LUNAR study led by Dr. Ticiana Leal, MD, and her esteemed colleagues, a discovery with the potential to revolutionize the management of metastatic non-small-cell lung cancer (NSCLC) has emerged. This study focused on patients who had experienced disease progression following platinum-based therapy, a group often faced with limited treatment options. The primary objective of the study was to assess the efficacy and safety of TTFields therapy when combined with standard systemic therapy. The results of this study were nothing short of remarkable. Dr. Leal stated, “The randomized, pivotal…

Allen Wilbanks asked Ticiana Leal, MD from the Winship Cancer Institute of Emory University, about her thoughts on the overall impact of TTFields treatment on the lives of patients with lung cancer.Ticiana Leal, MD, shared her perspective, emphasizing the challenges posed by lung cancer and the potential benefits of TTFields treatment for patients, particularly in the second line and beyond. She highlighted that this treatment offers an opportunity to improve survival without introducing additional systemic toxicities or compromising the quality of life.Watch the full interview here

Ticiana Leal, MD, a distinguished oncologist from the Winship Cancer Institute of Emory University, shared her insights during a discussion on the use of Electric Field (ED) therapy for lung cancer, addressing the ongoing challenges and areas for future research. In response to a question posed by Allen Wilbanks, Dr. Leal remarked, “Yeah, I think we’re going to continue to investigate the use of TT fields in non-small cell lung cancer.”With a poised demeanor, Dr. Leal highlighted the importance of comprehending how to integrate TT (Tumor Treating) fields into the existing landscape of systemic therapies. She emphasized this need, not…

By: Allen Wilbanks Date: September 29/2023 At the conference, Pankit expressed gratitude for another great talk, saying, “Thank you, Pankit for another fantastic talk. It’s my honor now to introduce Laura Michaelis, MD, a leader in myeloid malignancies at ASH and SWAG. Thank you, Laura.” Laura Michaelis began her presentation by acknowledging her pleasure to be there and shared two important lessons learned so far – the value of presentation slides and the need for humor. She then delved into essential thrombocythemia, emphasizing the critical importance of accurate diagnosis before treatment. Dr. Michaelis highlighted the significance of thorough diagnostics, especially…

In a recent interview, Peter Fasching, MD, Professor of Women’s Cancer Specialist at the University Hospital in Erlangen, Germany, discussed the findings from the NATALEE trial, focusing on the role of ribociclib in reducing the risk of cancer recurrence in early breast cancer patients while maintaining their quality of life. Dr. Fasching explained that ribociclib is a CDK4/6 inhibitor that can halt the cell cycle and send cells into senescence, making it a promising treatment option for early breast cancer patients.The Natalie trial, which involved over 5,000 patients, revealed that adding ribociclib to standard endocrine treatment resulted in a significant…

AVEO Oncology Fotivda Video Pre-Roll

In a recent discussion on the long-term efficacy and safety of TT field treatment for lung cancer, Allen Wilbanks raised an important question. Ticiana Leal, MD, an esteemed expert from the Winship Cancer Institute of Emory University, provided valuable insights into this topic.Dr. Leal began by highlighting the extensive experience with TT field treatment in patients with glioblastoma. She noted that real-world results for glioblastoma patients have consistently shown efficacy, safety, and improved quality of life, aligning with the landmark trials that led to the approval of TT fields in conjunction with temozolomide.Transitioning to non-small cell lung cancer, Dr. Leal…

In a recent discussion, Ticiana Leal, MD, sheds light on TD Fields treatment for non-small cell lung cancer. This innovative approach offers a unique localized therapy with potential systemic immune effects. However, Dr. Leal emphasizes that it doesn’t replace traditional treatments but complements them. She hints at exciting synergy possibilities when combined with systemic therapies. To learn more, watch the video for a deeper understanding of this groundbreaking approach.Watch the full interview with Ticiana Leal, MD here.

By: Allen Wilbanks Date: September 28/2023 Paolo Strati, MD, an assistant professor at the Anderson Cancer Center in Houston, Texas, delivered a comprehensive presentation on bispecific antibodies and their comparison to CAR T-cell therapy for patients with diffuse large B-cell lymphoma and follicular lymphoma. Dr. Strati emphasized the importance of collaboration in the field and discussed the development of bispecific antibodies, highlighting their journey from single-chain variable fragments to FDA approval. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register –…

By: Allen Wilbanks Date: September 28, 2023 Raajit Rampal MD. PhD, offered a glimpse of what the audience could expect. He mentioned, “We’ll have Rajith talking about Jack one, whether inhibiting it is a good thing or not so much, and what exactly it means in our patients.” He then introduced Steve O, who would delve into Nf Kappa b and present his much-talked-about ACVR research from the last ASH meeting. Rampal introduced the esteemed speakers, acknowledging Steve O from Washu and himself, Raajit Ramal from Stone Kettering. With a playful tone, he acknowledged the potential for missteps, saying, “So…

By: Allen Wilbanks Date: September 27/2023 Swetha Kambhampati, MD, presented at a conference with gratitude to the organizers and Dr. Flowers for the opportunity. She discussed innovative approaches for relapse refractory Hodgkin lymphoma. Dr. Kambhampati outlined her talk, covering BV and PD-1 inhibitors as salvage treatments, novel combinations, emerging immunotherapies, targeted treatments, and the role of stem cell transplants. Standard treatment involves salvage chemotherapy and autologous stem cell transplant, with room for improvement in response rates. BV and PD-1 inhibitors are increasingly used in earlier treatment lines, showing high response rates. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS…

Ticiana Leal, MD, from the Winship Cancer Institute of Emory University, shared her insights during a discussion with Allen Wilbanks regarding the promising potential of TT fields (Tumor Treating Fields) as a treatment modality for cancer patients.When asked about patient subgroups that might benefit more or less from TT field treatment, Dr. Leal responded with a wealth of knowledge and confidence. “I think, from the results of the Lunar trial,” she began, “what we saw was a striking improvement in overall survival in the ICI-treated subgroups.” She went on to elaborate, emphasizing the significance of combining immune checkpoint inhibitors (ICI)…

In this informative video, viewers will gain valuable insights into the groundbreaking research discussed by medical experts Ticiana Leal, MD, from the Winship Cancer Institute of Emory University, and Allen Wilbanks. The discussion revolves around the implications of recent findings for clinical practice in the field of oncology.Dr. Ticiana Leal begins by highlighting the significance of the study, emphasizing its novelty in demonstrating an improvement in overall survival for patients who have previously undergone platinum-based chemotherapy and are now being treated with immune checkpoint inhibitors (ICIs) as a first-line therapy. She underscores the importance of these findings as a potential…

By: Allen Wilbanks Date: September 27, 2023 Stephen Oh, MD PhD, took the podium to present his research in a room filled with anticipation. He began with a casual tone, saying, “I just wanna level set for the audience here. I’m gonna try to keep this science-y. I can’t promise you I won’t say something stupid.” He humorously added, “And, since I have two talks, if you wanna do a gladiator-style thumbs up or thumbs down after the first one, as to whether I’m allowed to proceed, I’m okay with that.” REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS…

By: Allen Wilbanks Date: September 27,2023 In a recent presentation, Elizabeth Brem, MD shared her perspective on the utilization of minimal residual disease (MRD) technology in clinical trials and its potential to transform patient care. She emphasized the various applications of MRD, including its role in guiding time-limited therapies to reduce toxicity, intensifying or extending therapy based on patient needs, and altering therapy strategies, especially in conditions like CLL. Dr. Brem noted that solid tumor colleagues have been more advanced in utilizing MRD technology clinically, while the lymphoma community is catching up to leverage it for patient care improvements. REGISTER NOW…

In a groundbreaking lunar trial, Ticiana Leal, MD, a distinguished expert from the Winship Cancer Institute of Emory University, spearheaded a Phase three study that promised to reshape the landscape of cancer treatment. This global, randomized study aimed to scrutinize the safety and efficacy of tumor treating fields (TT fields) therapy in conjunction with standard-of-care therapies. The subjects of this trial were patients grappling with advanced non-small cell lung cancer, a cohort that had experienced progression after undergoing platinum-based chemotherapy.In a nutshell, the primary objective was to fathom the impact of TT fields therapy, either combined with an immune checkpoint…

Ticiana Leal, MD, is at the forefront of an intriguing and evolving discussion centered on the mechanism underlying tumor treating fields (TT fields). These fields are a topic of great interest in the field of oncology, and Dr. Leal’s expertise shines through as she delves into the question at hand: how do tumor-treating fields actually work?TT fields, a novel approach in cancer therapy, harness the power of electric fields to interact with electrically charged components within the human body, specifically targeting dividing cancer cells. Their precise mode of action revolves around disrupting the crucial process of mitosis, where cells divide…

By: Allen Wilbanks Date: September 27, 2023 Myeloproliferative neoplasms (MPNs) are a group of blood disorders characterized by the overproduction of blood cells in the bone marrow. Andrew Kuykendall, MD, a well-known hematopathologist and engaging speaker, recently addressed the topic of “WHO versus ICC and the Implications within MPNs” in a presentation. Despite not being directly involved in either classification system, Dr. Kuykendall offered a unique third-party perspective on the matter, comparing and contrasting the two systems and their implications for MPNs. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU -…

By: Allen Wilbanks Date: September 27 /2023 John Leonard, MD, a prominent figure in the field of oncology, delivered a thought-provoking presentation at a medical conference. His words were a reflection of his deep commitment to improving patient outcomes and quality of life. In his address, he discussed various aspects of treating lymphomas, particularly follicular lymphoma and diffuse large B cell lymphoma, emphasizing the importance of considering these factors when making treatment decisions. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open…

By: Allen Wilbanks Date: 09/27/2023 William Shomali, MD, is a respected expert in systemic mastocytosis, known for his collaborative work with Jason Gottlieb at Stanford University. In a recent presentation, he shared valuable insights on this complex condition. Dr. Shomali began by expressing gratitude for the invitation and acknowledged MD Education for arranging the event. He then delved into systemic mastocytosis, emphasizing its challenging diagnosis due to the loss of granules in fixed tissue samples. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU -…

By: Allen Wilbanks Date: 09/27/2023 REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Sandeep Dave, MD, discussed the challenges of classifying and treating various blood cancers, including diffuse large cell lymphoma, follicular lymphoma, mantle cell lymphoma, and peripheral T cell lymphomas. He emphasized the importance of genomic profiling in understanding the heterogeneity of these diseases. For diffuse large cell lymphoma, Dr. Dave highlighted the complexity of subgrouping patients based on genetic alterations,…

By: Pankit Vachhani, MD Date: 09/22/2023 REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com The audience was eagerly awaiting the insights of Dr. Pankit Vachhani, a long-time friend and mentee. As the presentation commenced on “Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes,” attendees were in for a comprehensive exploration of the topic. Despite his usual penchant for occupying the back seats, Dr. Vachhani humorously admitted, “Usually, I’m the guy who sits in…

By: Christopher Flowers, MD Date: 09/22/2023 Dr. Christopher Flowers of MD Anderson Cancer Center expressed his gratitude to Sandeep for his excellent talk, acknowledging it as a perfect precursor to his own discussion on integrating tools into clinical practice and trials. Dr. Flowers shared his relevant disclosures, mainly involving his role as a consultant in lymphoma therapy development and his work in the Division of Cancer Medicine. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US…

In a conversation hosted by Allen Wilbanks, Solange Peters, MD, PhD, a full professor and chair of medical oncology specializing in thoracic malignancies at the University Hospital of Lausanne in Switzerland, discussed the remarkable findings from the CheckMate 227 trial, particularly the six-year outcomes of Nivolumab and Ipilimumab as first-line treatment for metastatic non-small cell lung cancer.Dr. Peters emphasized that Nivolumab and Ipilimumab, being chemotherapy-free, offer an intriguing approach based solely on immune responses. Another key aspect is that the treatment stops at two years, allowing researchers to evaluate the long-term effects of promoting an immune response.Regarding the use of…

an AML-ALL US Focus Meeting 2023 video

Jack West, MD is an associate professor in medical oncology specializing in thoracic oncology at the City of Hope Comprehensive Cancer Center in the Los Angeles area. Recently, he discussed the highly anticipated FLAURA2 trial during the World Conference on Lung Cancer in Singapore. In his words, “Hi, I’m Jack West. I’d like to talk about the FLAURA2 trial, which was among the most anticipated presentations at the just completed World Conference on Lung Cancer in Singapore.”The FLAURA2 trial aimed to compare the efficacy of Osimertinib as a single agent versus Osimertinib combined with chemotherapy as a first-line treatment for…

In a discussion with Allen Wilbanks from Oncology Tube, Brandon McNaughton, CEO & Founder of Akadeum Life Sciences, shed light on the innovative Akadeum’s human T cell activation and expansion kit and its impact on cell therapy. McNaughton explained the advantages of their microbubble-based technology compared to traditional methods, highlighting its gentleness, scalability, and compatibility with various cell culture systems.He stated, “What’s different about what we do, which is using tiny floating particles, we call them micro bubbles to essentially reach into a sample, essentially a blood bag that was derived from a phoresis or Luca pack. We use microbubbles…

In the pivotal phase 3 LUNAR study, Ticiana Leal, MD, and her colleagues made a groundbreaking discovery that could revolutionize the treatment of metastatic non-small-cell lung cancer (NSCLC) in patients who have experienced disease progression following platinum-based therapy. The study, which aimed to evaluate the efficacy and safety of TTFields therapy in combination with standard systemic therapy, yielded remarkable results.Dr. Leal stated, “The randomized, pivotal phase 3 LUNAR study provides level 1 evidence that TTFields therapy, an innovative, locoregional treatment method, applied concomitantly with standard systemic therapy significantly improves overall survival in patients with metastatic non-small-cell lung cancer following progression…

OneOncology, a rapidly expanding national platform for independent medical practices, proudly announces the completion of 25 distinctive oncology and hematology pathways. These pathways are now integrated into the platform’s clinical decision support tool, a testament to OneOncology’s dedication to precision and excellence. Lisa Sowinski-Raff PharmD, serving as Vice President of Pharmacy Services, plays a pivotal role in this achievement.OneOncology adopts a physician-driven approach to pathway development, led by Medical Director Edward Arrowsmith, MD. Experts in gastrointestinal, genitourinary, breast, lung, and hematology, along with disease subject matter experts in gynecology and head and neck specialties, meticulously craft and continuously update these…

Timothy Looney, PhD – Senior Director, Immunology and Bioinformatics at Singular Genomics By: Timothy Looney, PhD Date: 9/12/2023 The topic at hand revolves around “Immune-Related Adverse Events (IRAEs)” in the context of cancer treatment using “Immune Checkpoint Inhibitors (ICIs).” Timothy Looney, a prominent researcher with a PhD, discusses the significance of IRAEs in cancer immunotherapy. IRAEs are adverse events that occur when therapeutic agents like ICIs activate T cells, causing them to mistakenly target healthy tissues, leading to damage or destruction. These events, which can range from mild to life-threatening, are a major concern in cancer immunotherapy due to the…

The interview with Jill O’Donnell-Tormey, PhD, delves into the vital topic of cancer immunotherapy and research, emphasizing the transformative potential of harnessing the human immune system to combat various forms of cancer. Throughout the conversation, O’Donnell-Tormey provides valuable insights and perspectives on key areas of focus within the field. Here are some direct quotes from her on these topics:On the mission of the Cancer Research Institute (CRI):”We are a non-profit organization that’s been around for 70 years with the singular view that your immune system could be harnessed as a way to treat, control, and potentially cure all cancers.”On the…

In the interview, Susan Pandya, MD, Vice President of Clinical Development at Servier Pharmaceuticals, discusses the pivotal FDA acceptance and priority review for TIBSOVO in the treatment of IDH1-mutated relapsed or refractory myelodysplastic syndromes (MDS). The acceptance marks a significant milestone in advancing targeted therapies for patients facing limited options in this challenging disease context.TIBSOVO’s clinical data submission showcased remarkable results, with complete remissions achieved in approximately 40% of patients and an overall response rate of 83.3% among those with relapsed or refractory IDH1-mutated MDS. These outcomes far exceed existing treatment options, underscoring TIBSOVO’s potential as a transformative therapy for…

Marwan Fakih, MD – City of Hope – FDA Approval of LONSURF in combination with Bevacizumab The FDA approval of Lonsurf plus Bevacizumab represents a significant breakthrough in the treatment of metastatic colorectal cancer. This combination therapy offers new hope for patients who have previously exhausted their treatment options, providing substantial improvements in both overall survival and progression-free survival. The clinical trial results from the Sunlight trial have solidified Lonsurf plus Bevacizumab as the standard third-line treatment for metastatic colorectal cancer, with potential implications for future research and control arms in clinical trials. Physicians are encouraged to consider this combination…

Joshua Brody, MD – Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount SinaiHess Center for Science and Medicine – Pattern recognition receptor agonists in pathogen vaccines mediate antitumor T-cell cross-priming What is the role of primed CD8 T-cells in cancer immunotherapies, and how does their recognition of tumor antigens presented on MHC-I contribute to the antitumor response?What are the critical factors in loading dendritic cells (DC) with tumor antigens, and how can we optimize this process to enhance antitumor T-cell responses?Can you explain the advantages and limitations of using neoantigen vaccines based on individualized tumor exome and RNA…

In the interview with Allen Wilbanks of OncologyTube, Peter Langmuir, the Vice President of Oncology Drug Development at Incyte, discussed the Agave 201 trial and its outcomes. Mr. Langmuir explained, “The Agave 201 trial was a clinical trial in patients with chronic GVHD, looking at the drug axatilimab, a monoclonal antibody against the CSF1 receptor. That was originally developed by our partners at syntax. And this trial was initiated by them to do two things. First of all, one was to try to identify the most appropriate dose of axatilimab to use in these patients based on both safety and…

The recent approval by the Food and Drug Administration (FDA) of mirvetuximab soravtansine-gynx (Elahere) marks a significant advancement in the treatment landscape for adult patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. This article aims to provide oncologists with a comprehensive overview of the efficacy, safety profile, and prescribing considerations associated with this novel therapeutic agent. Efficacy Evaluation: Study 0416 Mirvetuximab soravtansine-gynx’s (Elahere) approval was based on data from Study 0416 (MIRASOL), a pivotal multicenter trial involving 453 patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. Patients enrolled in the study had…

Mark Schoenberg, MD- UrologyGenitourinary (GU) CancerBladder Cancer-The Montefiore Medical Center and The Albert Einstein College of Medicine at UroGen Pharma What is UGN-102, and what is its potential role as the first non-surgical therapy for LG-IR-NMIBC? Could you explain the primary endpoints achieved in both the ATLAS and ENVISION clinical trials for UGN-102? In the ATLAS trial, UGN-102 showed a 55% reduction in the risk of recurrence, progression, or death compared to TURBT. How significant is this finding for patients with LG-IR-NMIBC? What was the complete response rate at three months observed in the ENVISION trial, and how does it…

Elizabeth Brem , MD discusses the design and outcomes of the study referred to as 1826. The study aimed to enhance outcomes and address toxicities in Hodgkin lymphoma treatment. Nivolumab’s potential benefits in comparison to brentuximab within the AVD backbone were explored. Additionally, Brem highlights the collaborative nature of the study, involving adult and pediatric cooperative groups, Canadian cooperative groups, and the children’s oncology group. This collaboration played a pivotal role in the trial’s success, enabling rapid accrual and earlier achievement of primary endpoints.Elizabeth Brem emphasizes that the study achieved its primary objective by improving progression-free survival in patients with…

Shirin Attarian, MD addresses the escalating incidence of head and neck cancer and highlights that most cases, particularly oropharyngeal cancers, are driven by HPV virus infection. She discusses HPV vaccination recommendations, suggesting that individuals between 11 and 26 years old should be vaccinated, potentially starting from age 9. Vaccination for those aged 27-45 is possible after physician consultation but might be less effective due to prior exposure. Beyond 45, there are no current vaccination recommendations. Attarian explains that despite younger generations getting vaccinated, the incidence of head and neck cancer is anticipated to rise in older individuals who aren’t vaccinated.…

Nataliya Mar, MD Clinical Associate Professor in the Division of Hematology/Oncology at the University of California Irvine, provides GU ASCO Updates [2023]. What were the VESPER trial results? What were the CONTACT-03 trial results? In the case of the 68-year-old man with metastatic prostate cancer, who had initial response but then developed PSA rise, what are the key considerations when selecting treatment options for patients with somatic and germline DDR alterations? How do PARP inhibitors fit into the treatment landscape? What were the TALAPRO-2 trial results?

Rafael G. Amado, M.D., President, Head of Global Oncology Research and Development, leading and overseeing the company’s global oncology research and development activities. In a pivotal Phase 3 randomized clinical trial, niraparib maintenance therapy has demonstrated remarkable efficacy for patients recently diagnosed with advanced ovarian cancer following initial platinum-based chemotherapy. This trial, involving 384 participants, unveiled the significant potential of niraparib in extending progression-free survival rates by a substantial 55% when compared to a placebo control group. Notably, the treatment’s effectiveness was observed across diverse patient subsets, regardless of their biomarker status or the presence of residual disease. These findings…

Pre-Roll Example

Advertising on OncologyTube For A Limited Time No Contracts! Pay As You Go! Book Now! or Contact Us for More Info or Call 1 (951) 944-2173 (Discounts available for 3, 6, and 12 month contracts) Why OncologyTube? $120 CPM the lowest in the industry (for a limited time only) 90% of our unique content is created by MD oncologists for oncologist. We work with the biggest pharmaceutical, research hospitals, and universities in the world. The most well-known oncology KOLs and researchers contribute to our platform. 10,000+ NPI-verified oncologists subscribed to our monthly eNewsletter. Thousands more worldwide. 20,500+ Social Media followers mostly…

Sanam Loghavi is Assistant Professor, Department of Hematopathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX The talk covered the emerging field of menin inhibition in AML, shedding light on its potential as a novel therapeutic strategy. The enthusiasm around this development was palpable in the presentation, reflecting the speaker’s excitement for the advancements in understanding and treating AML. Additionally, the evolving classification of AML was discussed, showcasing the dynamic nature of the field and the constant discovery of new entities within it. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US…

Yasmin Abaza, MD Assistant Professor, Medicine (Hematology and Oncology) In a captivating interview, Yasmin Abaza, MD, an esteemed Assistant Professor of Medicine at Northwestern University, delved into her research focus on Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS). Offering a comprehensive overview of immune cell therapies for these conditions, Dr. Abaza touched upon the historical struggles encountered in achieving successful outcomes. She candidly highlighted the limited success observed thus far while shedding light on the promising agents currently undergoing clinical trials. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU -…

Jessica Altman, MD – Professor, Medicine, Hematology Oncology Division; Feinberg School of Medicine Jessica Altman, MD, a dedicated professional at Northwestern University in Chicago, recently participated in her first conference, which proved to be a remarkable experience. At this event, she engaged in a thought-provoking debate with Dr. Dauver, focusing on the treatment of acute myeloid leukemia (AML) in adults with newly diagnosed cases. The debate centered on the comparison between triplet-based therapy and sequential therapy. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU -…

Elias Jabbour, MD – Professor, Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX Elias Jabbour, MD a dedicated professional at MD Anderson in Houston, Texas, recently presented groundbreaking insights at a conference. Formerly dire disease survival rates have been revolutionized, with ten-year survival now at an impressive ninety percent within four to five years. This transformation represents a new standard of care and a remarkable advancement for patients. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open…

The discussion focuses on the changing landscape of treatment for mutated acute myeloid leukemia (AML). The speaker emphasizes the significance of mutation profiles in AML patients, which can have prognostic or therapeutic implications. Poultry inhibitors are believed to have a lasting impact, with many candidates already approved or under investigation. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com The session’s agenda involves a brief introduction followed by experts discussing various aspects of…

Bijal Shah, MD, MS- Hematology/Oncology- Moffitt Cancer Center Bijal Shah MD, MS, emphasizes the positive outcomes of CAR T cell therapy for patients with relapsed refractory conditions, particularly those who have experienced multiple relapses and high tumor burdens. They highlight the success achieved with CAR T therapy, especially after treatment with Blinatumomab (Blina) and Inotuzumab Ozogamicin (I know). REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Bijal Shah MD, MS,…

Charles G. Mullighan, MBBS (Hons), MSc, MD-Member, St. Jude Faculty-Deputy Director, Comprehensive Cancer Center-St. Jude Children’s Research Hospital Charles Mullighan, MD, delves into the genomic classification of Acute Lymphoblastic Leukemia (ALL) and its diagnostic approaches. He covers three main areas: B-cell ALL (BOL), implications for risk stratification and diagnosis, and insights into the classification of T-cell ALL (TOL). REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com After a decade of genomic research,…

Sayeh Lavasani, MD of UCI Health gives an Update in Breast Cancer at MOASC’s Spotlight on Oncology NATALEE’s study focused on comparing adjuvant ribocyclib plus a non-steroidal AI versus an AI alone in high-risk, early-stage, hormone receptor-positive breast cancer patients. The ribocyclib was administered at a lower dose of 400 milligrams daily for three weeks on and one week off, over three years. This study showed improvements in invasive disease-free survival, as well as trends towards enhanced overall survival in a three-year follow-up. These findings suggest an additional treatment option to reduce the risk of recurrence in earlier-stage hormone-positive breast…

Regina Myers, MD, MSCE, is an instructor in the Cancer Center at Children’s Hospital of Philadelphia. Regina Myers, MD expresses gratitude for the audience’s presence and thanks the event organizers for the invitation. They introduce themselves as a pediatric oncologist speaking at an adult conference, focusing on pediatric AAA (acute lymphoblastic leukemia) and 4-1BB CAR T cell therapies. They mention the high complete response (CR) rates of up to 97% achieved with CAR19 (CAR targeting CD19), but also note the significant challenge of disease relapse after CAR19 treatment, especially in pediatric and adult patients. They attribute relapse to two main…

Shira N. Dinner, MD- Robert H Lurie Cancer Center Shira N. Dinner, MD discussed several studies focused on the treatment of acute lymphoblastic leukemia (ALL) in older adults, particularly those aged 55 and above. The presentation highlighted the challenges and outcomes associated with different treatment approaches. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTSAML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Shira N. Dinner, MDfirst emphasized the historical poor outcomes for older adults with ALL, with survival rates being notably lower compared to…

Hagop Kantarjian, MD is professor and chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center Hagop Kantarjian, MD shared exciting updates and progress in the treatment landscape. Notably, some of the predictions made back in 2010 are now proving to be successful. Initiatives like the development of the blinatumomab and inotuzumab therapies started in 2008 and by 2010, it was clear that using them as standalone treatments would not be effective, prompting a shift towards combination therapies. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTSAML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/AML-ALL EU -…

When your patient is diagnosed with a blood cancer such as chronic lymphocytic leukemia (CLL), it’s important to remember that in addition to their physical health, their mental health is a critical part of their overall well-being.1 From initial diagnosis through remission, it’s essential to ensure patients are equipped with tools and resources to help them manage the various emotions that come with a diagnosis and know how to seek professional help when needed. Many patients feel a certain stigma around mental health, so it’s important to initiate the conversation. Helping patients figure out how to create an action plan…

Nitin Jain, M.D., is an Associate Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas, USA. Nitin Jain, MD, discussed relapsed/refractory T-cell acute lymphoblastic leukemia (TLL) and the need for new therapies due to the ineffectiveness of current treatments. They highlighted studies that assessed outcomes in relapsed TLL, demonstrating a median survival of four to six months, indicating the significant unmet medical need. Nitin Jain, MD, also mentioned the criteria for defining early T-cell precursor leukemia (ETPL) based on gene expression and flow cytometry markers. They discussed different approaches for treating…

Bijal Shah, MD, MS- Hematology/Oncology- Moffitt Cancer Center Bijal Shah MD, MS, emphasizes the positive outcomes of CAR T cell therapy for patients with relapsed refractory conditions, particularly those who have experienced multiple relapses and high tumor burdens. They highlight the success achieved with CAR T therapy, especially after treatment with Blinatumomab (Blina) and Inotuzumab Ozogamicin (I know). REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Bijal Shah MD, MS,…

Marina Konopleva, MD, PhD – University of Texas MD Anderson Cancer Center and Albert Einstein College of Medicine Jack and Pearl Resnick Campus The discussion revolved around patients with B-cell acute lymphoblastic leukemia (ALL) that had a gene expression signature similar to Philadelphia chromosome-positive ALL (Ph+ ALL) but lacked the characteristic genetic abnormalities. This subgroup, referred to as “PH-like ALL,” comprised around 20-30% of ALL cases, with a higher prevalence in pediatric patients. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ ML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU -…

Marlise Luskin,MD, MSCE- Medical Oncology- Dana-Farber/Mass General Brigham Hematology/Oncology Fellowship Program and education director for the adult leukemia program. The presentation focused on the use of the drug venetoclax (and its related drugs) in the treatment of acute lymphoblastic leukemia (ALL), particularly relapse refractory ALL. The speaker outlined the significant progress that has been made in the treatment of this disease, including various therapies like blinatumomab, iituzumab, and CAR T cell therapy, which have shown improvements but still leave certain subsets of patients with unmet needs. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content…

Elias Jabbour, MD- Professor, Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX Elias Jabbour, MD discussed the potential treatment options for patients facing relapsed leukemia during a medical presentation. He emphasized the importance of considering complementary strategies rather than competing ones. Dr. Jabbour advocated starting with bispecific and immunotherapy approaches before utilizing CAR T-cell therapy due to their positive impact on survival. He referred to the dire prognosis of relapsed patients, comparing it to a death sentence, and highlighted the challenges associated with traditional treatments like transplantation. REGISTER NOW TO JOIN US AT THESE UPCOMING…

IMpower010 & Atezolizumab: The trial has cemented the significance of atezolizumab in the potential treatment options for lung cancer, especially as an adjuvant in non-small cell lung cancer (NSCLC). Debate & Discourse: While promising, the broadened approval and usage of atezolizumab have sparked meaningful debate regarding its universal applicability and effectiveness. Unbiased Presentation: The oncological community must remain vigilant, ensuring that data and results are presented without bias, offering patients and practitioners clear insights into potential treatment modalities. In the vast realm of oncology, lung cancer remains a predominant concern and focus of rigorous scientific research. At the forefront of…

Ryan D. Cassaday,MD- Physician-Fred Hutch Ryan Cassaday, MD emphasizes the importance of the topic at hand and humorously compares the debate between inotuzumab and blinatumumab to choosing between seat belts and airbags, highlighting his belief that both treatments have significant roles to play. Dr. Cassaday focuses on presenting data supporting inotuzumab, specifically in the context of older adults with pH-negative B cell acute lymphoblastic leukemia (ALL). He discusses studies from MD Anderson and the German Cooperative Group that showcase the effectiveness of inotuzumab in inducing morphologic remission and achieving favorable survival curves, despite challenges such as toxicity. REGISTER NOW TO…

Anjali Advani, MD- Hematology and Medical Oncology- Cleveland Clinic Anjali Advani, MD, begins her talk by expressing gratitude for the invitation to speak. She proceeds to discuss the integration of blinatumomab into upfront therapy for acute lymphoblastic leukemia (ALL). Dr. Advani explains that blinatumomab, a bispecific antibody engaging CD3 and CD19, effectively induces T-cell proliferation and apoptosis of leukemia cells. She emphasizes blinatumomab’s advantages, including its lack of attached chemotherapy, reduced risk of complications, and potential immune effects. Dr. Advani discusses ongoing efforts to refine blinatumomab’s administration and dosage for optimal patient outcomes. REGISTER NOW TO JOIN US AT THESE…

Aaron Logan, MD, PhD- Associate Professor of Clinical Medicine, Division of Hematology/Oncology, UCSF Aaron Logan, MD PhD, conveyed his gratitude to the event organizers and acknowledged the valuable input of different perspectives at the meeting. He highlighted the critical role of assessing minimal residual disease (MRD) in leukemia treatment strategies. Drawing on data from various studies, Dr. Logan underscored how MRD presence or absence can accurately predict survival outcomes in patients undergoing therapy for leukemia. However, he also acknowledged the limitations of MRD assessments, as they don’t always perfectly predict relapse or remission. He discussed the importance of precise MRD…

Jalen Patel, MD – City of Hopeaugust 21, 2023Drawing from data provided by ASCO and Friends of Cancer Research, the study endeavors to characterize the eligibility criteria employed in advanced prostate cancer investigations. The primary objective centers on ensuring that the clinical trial parameters accurately reflect the broader population.The classification involves three distinct categories: exclusion, conditional inclusion, and instances where criteria were not reported. Upon scrutinizing the criteria of interest, the analysis reveals a predominant tendency among trials to exclude individuals with brain metastases, HIV, hepatitis B and C, as well as concurrent malignancies. The subsequent breakdown of four figures…

Akasha Dukkipati, MD at City of Hope August 21, 2023 Akasha Dukkipati, MD at City of Hope, conducted an analysis of urothelial cancer studies spanning a decade, from 2012 to 2022. The aim was to scrutinize eligibility criteria due to concerns raised by a collaborative statement from ASCO and Friends of Cancer Research. The joint statement underscored the underrepresentation of certain clinical attributes resulting from overly stringent eligibility standards in clinical trials. The physician’s team specifically focused on advanced urothelial cancer studies, examining four primary exclusion factors: concurrent malignancies, brain metastases, hepatitis B and C infections, and HIV. Their findings…

Mark Litzow, MD- Hematologist, Oncologist, Palliative Care Specialist- Mayo Clinic In a presentation delivered by Mark Litzow, MD, the speaker expresses gratitude for the invitation and acknowledges the organizers. The speaker humorously remarks that they are unsure who needs transplants nowadays. They express their intention to address the question of who needs transplantation in the first remission (CR1) and highlight the importance of relapse and its relation to transplant outcomes. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register –…

Branko Cuglievan, MD- Assistant Professor, Department of Pediatrics Patient Care, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX – Section Chief, Leukemia/Lymphoma, Department of Pediatrics Patient Care, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX Branko Cuglievan, MD, expresses gratitude for being invited to an adult conference to discuss pediatric data and challenges. He addresses the differences in age distribution between acute myeloid leukemia (AML) and pediatric leukemias. Dr. Cuglievan emphasizes the lower incidence of pediatric AML cases and the struggle to enroll sufficient patients for studies due to the dispersed…

Charles G. Mullighan, MBBS (Hons), MSc, MD-Member, St. Jude Faculty-Deputy Director, Comprehensive Cancer Center-St. Jude Children’s Research Hospital Charles Mullighan, MD, expresses gratitude for the invitation to speak at the meeting and discusses the genomic classification of leukemia, particularly focusing on B-cell acute lymphoblastic leukemia (B-ALL) and T-cell acute lymphoblastic leukemia (T-ALL). He covers three main areas: B-ALL genomic classification, its implications for diagnosis and risk assessment, and recent unpublished data on T-ALL classification. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open…

Elias Jabbour, MD- Professor, Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX The talk, delivered by Elias Jabbour, MD, centers around the treatment paradigm for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), proposing a shift from traditional chemotherapy to tyrosine kinase inhibitors (TKIs) and immunotherapy. Dr. Jabbour discusses the historical use of allogeneic stem cell transplantation and its limitations. The presentation delves into data from MD Anderson and other studies, emphasizing the challenge of achieving high survival rates. The concept of complete molecular remission (CMR) is underscored, with an emphasis on early molecular response deepening.…

Wendy Stock, MD – Anjuli Seth Nayak Professor of Medicine- The University of Chicago Medicine In this presentation, Wendy Stock, MD, addresses optimizing outcomes for adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Dr. Stock expresses gratitude for the opportunity and highlights the importance of such meetings, drawing from her own experience when starting her career. She discusses the positive changes in patient outcomes, particularly emphasizing minimal residual disease (MRD) eradication as a key goal. The importance of blending new therapies with older approaches and using less aggressive treatment for older patients and AYAs is mentioned. Dr. Stock…

Marina Konopleva, M.D., Ph.D.- Professor, Department of Oncology (Medical Oncology) Professor, Department of Molecular Pharmacology- Albert Einstein College of Medicine In this presentation by Marina Konopleva, MD, she covers the resistance mechanisms and potential combination strategies related to venetoclax, an AML (acute myeloid leukemia) treatment. Despite overlapping slides, she delves into the topic, shedding light on resistance challenges. Konopleva elaborates on the mechanism of action, targeting BCL-2, and its interaction with mitochondrial proteins. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/…

Tapan Kadia, MD- Professor, Department of Leukemia, Division of Cancer Medicine, M.D. Anderson Cancer Center, Houston, TX In this presentation Tapan Kadia, MD discusses the challenge of high relapse rates despite achieving complete remissions with newer therapies. Historical attempts at maintenance therapy are reviewed, with improvements seen in relapse-free survival but not overall survival. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Dr. Kadia highlights the success of oral hypomethylating…

Hetty Carraway, MD- Hematology and Medical Oncology- Cleveland Clinic Hetty Carraway, MD, delivers a comprehensive discussion on immune-based and novel strategies to enhance outcomes for patients with myelodysplastic syndromes (MDS). The focus lies on unraveling the intricate relationship between the immune system and MDS pathogenesis, exploring immune interventions like immune checkpoint inhibitors (ICIs), and addressing challenges related to immune manipulation, mutational profiles, and the microenvironment. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus…

Andrew Artz MD- Hematologist-Oncologist- City Of Hope Andrew Artz, MD, expresses gratitude to the organizers and prior presenters, acknowledging the topic’s extensive coverage. Playfully, he considers sharing random pictures or dinner plans but proceeds to discuss his presentation’s content. He highlights the increasing use of allogeneic transplants, especially for older patients and those in first remission, attributing this rise to novel therapies. Dr. Artz emphasizes the challenge of relapse and the need to balance it against transplant-related toxicities. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open…

Yasmin Abaza, MD Assistant Professor, Medicine (Hematology and Oncology) Yasmin Abaza, MD discusses advancements and challenges in the treatment of Acute Myeloid Leukemia (AML) using immunotherapies. Over the past five decades, outcomes for AML patients have improved, but long-term survival rates remain low, highlighting the need for new treatment options. Allogeneic stem cell transplantation is a potent immunotherapy for AML, particularly in patients with intermediate or adverse risk disease. The transplantation’s effectiveness lies in the donor T cell’s ability to target and destroy leukemia cells through interactions with AML cells’ molecular markers. Despite its benefits, this approach is associated with graft-versus-host…

Dr. Ghassan Abu Alfa, MD with Memorial Sloan Kettering Cancer Center in New York, provides an update on the key findings of the Himalaya clinical trial. The trial, a phase 3 study, investigated the combination of darvalumab and tremelumab for patients with intractable hepatocellular carcinoma. The study involved a phase 3 clinical trial, comparing the combination therapy to sorafenib, the prevailing standard care at that time and widely used globally. The primary focus was on enhancing survival outcomes with the combination of Dervalumab and Tremelumab versus Sorafenib. Notably, the median overall survival was approximately 16.5 months for the combination therapy…

Dr. Jack West,MD an associate professor in medical oncology at City of Hope Comprehensive Cancer Center in Los Angeles, discussed a recent publication in the Annals of Oncology regarding the IMpower010 trial. The trial focused on the adjuvant use of atezolizumab and was initially presented by Dr. Heather Wakely and colleagues at ASCO 2021. The trial showed a statistically significant improvement in disease-free survival for patients with stage 2 to 3a resected non-small cell lung cancer and PD-L1 of 1% or higher who received adjuvant atezolizumab compared to placebo. While the trial demonstrated benefits in disease-free survival, further analysis reveals…

Naval Daver MD is an Associate Professor in the Department of Leukemia at MD Anderson Cancer Center. Naval Daver, MD expresses uncertainty and discusses the need for personalized treatment strategies. He mentions starting with a metaphor about eggs and ice cream preferences. They highlight the lack of data on triple therapy and the importance of considering individual differences. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com The talk shifts to triple…

Brian Andrew Jonas, M.D., Ph.D.- Hematology and Oncology – Hematology and Oncology – UC Davis Comprehensive Cancer Center The presentation discusses the management and treatment strategies for patients with high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) receiving hypomethylating agents (HMA) in combination with venetoclax. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Brian Andrew Jonas, M.D., Ph.D. discusses various aspects of this treatment approach, including dosing regimens, response…

Jessica Altman, MD – Professor, Medicine, Hematology Oncology Division; Feinberg School of Medicine The presentation discusses various aspects of treatment strategies for newly diagnosed acute myeloid leukemia (AML), focusing on optimizing therapy approaches and providing practical insights for healthcare professionals. It delves into considerations for patients who are not suitable for intensive chemotherapy, explores the use of different approved or accessible agents, and emphasizes the importance of achieving transfusion independence and improved quality of life for AML patients. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open -…

In the dynamic world of oncology, chemotherapy stands as a beacon of hope for many battling the formidable challenge of cancer. When diagnosed with cancer, patients are presented with a spectrum of treatment modalities, and one of the most crucial decisions revolves around when and how to administer chemotherapy. Amidst the plethora of choices, one term has steadily gained prominence: neoadjuvant chemotherapy. But what is neoadjuvant chemotherapy? And how does it distinguish itself from other treatment strategies? What is Neoadjuvant Chemotherapy? Stepping into the world of oncology, terms and treatments can often feel overwhelming. Amidst the myriad of terminologies, neoadjuvant…

Courtney DiNardo, MD- Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX Emerging as a beacon of hope in the realm of acute myeloid leukemia (AML) treatment, a new frontier is being forged through the synergistic power of innovative drug combinations. By intertwining the potency of IDH inhibitors like ivosidenib and enasidenib with hypomethylating agents and the precision of venetoclax, a novel therapeutic approach is taking center stage. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open…

Eytan M. Stein, MD – Hematologist-Oncologist – Memorial Sloan Kettering Cancer Center Discover the cutting-edge landscape of acute myeloid leukemia (AML) treatment with a focus on Revumenib and Ziftomenib, two promising menin inhibitors. Delving into the realm of AML therapy, this discussion navigates through the potential roles of Revumenib and Ziftomenib in treating relapsed and refractory cases, particularly among patients with KMT2A rearrangements and NPM1 mutations. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US…

Presented By: Brian Warnecke, DO – UC-Irvine Hematology Oncology Fellow, PGY-5 Date: August 12, 2023The presentation titled “Multi-omic Characterization of RCC1 Expression and its Association with Molecular Alterations, Immune Phenotypes, and Cancer Outcomes,” conducted by Brian Warnecke, D.O., a UC-Irvine Hematology Oncology Fellow in his PGY-5, unveils a comprehensive investigation into the multifaceted role of Regulator of Chromosome Condensation 1 (RCC1) in cancer development and progression. Collaboratively led by principal investigators Dr. Mohammed Al Hallak (Karmanos), Dr. Asfar Azmi (Karmanos), and Dr. Misako Nagasaka (UC Irvine), this research endeavor delves into the intricate interplay between RCC1 expression, molecular alterations, immune…

Presented By: Dalia Kaakour, MD – University of California, Irvine Date: Aug 12, 2023 In the realm of oncology and immunotherapy, the investigation into the safety and efficacy of immune checkpoint inhibitors (CPIs) takes a step forward with an insightful study by Dr. Dalia Kaakour, MD, MPH, from the University of California, Irvine’s Department of Medicine Division of Hematology and Oncology Fellowship Program. With an absence of any disclosures, this study delves into the realm of immune-related adverse events (irAEs) in patients afflicted by both solid tumors and advanced chronic kidney disease (CKD) who are undergoing treatment with CPIs. Traditionally,…

Presented By: Shirin Attarian, MD Date Aug 12, 2023 In the realm of oncology, Head and Neck Cancer stands as a significant challenge, both in terms of its prevalence and the intricacies surrounding its diagnosis and treatment. This complex and diverse set of malignancies affects millions across the globe each year, making it the seventh most common cancer worldwide. Amid the countless battles against this formidable adversary, the insights of medical professionals like Dr. Shirin Attarian have proven invaluable. Dr. Attarian’s meticulous review of Head and Neck Cancer reveals a landscape of statistics that underscore the urgency of continued research…

Alexander Edward Perl, MD, MS – Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania Alexander Edward Per, MD, MS emphasizes the need to unravel the intricacies of both primary and secondary resistance mechanisms associated with FLT3 inhibitors, highlighting their role in AML management. Discussions revolve around the potential of these inhibitors to target FLT3 mutations, while also addressing challenges such as polyclonality and the selection of resistant clones. The importance of achieving optimal disease response is underscored, with an emphasis on utilizing minimal residual disease (MRD) testing to guide treatment decisions and enhance patient outcomes. REGISTER…

Farhad Ravandi, MD is Janiece and Stephen A. Lasher Professor of Medicine and Chief of Section of Developmental Therapeutics in the Department of Leukemia at The University of Texas MD Anderson Cancer Center. In his compelling presentation, Farhad Ravandi, MD, a distinguished medical professional in the field of oncology, delves into the critical significance of minimal residual disease (MRD) assessment in the realm of acute myeloid leukemia (AML) treatment. As an accomplished hematologist, Dr. Ravandi brings his extensive expertise to the forefront, elucidating how achieving complete morphological remission is a pivotal determinant in long-term survival for AML patients. REGISTER NOW…

Refresh URL Changing Content

Spotlight on Oncology: Exploring the Latest Advances in Lung Cancer Research Date: August 12, 2023 Speaker: Sai-Hong Ignatius Ou, MD PhD Welcome to the 2023 MAOSC Spotlight on Oncology, a dynamic event that brings together leading minds in the field of lung cancer research to discuss groundbreaking developments and insights. This year’s event focuses on the latest advancements in lung cancer treatment, with a special emphasis on the management of lung cancer through various stages. At the helm of this enlightening discussion is the esteemed Dr. Sai-Hong Ignatius Ou, MD PhD. Dr. Ou is a distinguished Health Science Clinical Professor…

Updates in Lymphoma: Advancements in Treatment Strategies Date: August 12, 2023Presenter: Elizabeth Brem, MD (Clinical Associate Professor) In the ever-evolving landscape of oncology, particularly in the field of lymphoma treatment, significant strides have been made to improve patient outcomes and quality of life. Dr. Elizabeth Brem, a prominent figure in the field, delivered a comprehensive presentation on the recent updates in lymphoma treatment during the recent event. Dr. Brem is a Clinical Associate Professor renowned for her expertise and contributions to the field. Disclosures: Dr. Elizabeth Brem is associated with several pharmaceutical and biotech companies, reflecting her active engagement in…

Interview with Pankit Vachhani, MD Hematology Oncology- UAB Medicine Timestamps: 0:00:09 What is the objective of this study on indolent systemic mastocytosis (ISM)?0:00:50 How were patients with ISM randomized in this study, and what were the treatment groups?0:01:48 What was the primary endpoint measured in this study, and how was it assessed?0:02:20 What were the secondary endpoints evaluated in this study?0:03:19 What were the results regarding the mean change in total symptom score (TSS) between the avapritinib and placebo groups?0:04:17 How did avapritinib treatment impact serum tryptase levels in patients with ISM?0:05:02 Were there any notable differences in adverse events…

Amir T. Fathi MD Associate Professor of Medicine, Harvard Medical School Program Director, Center for Leukemia- Massachusetts General Hospital Join us on a journey to the forefront of Acute Myeloid Leukemia (AML) treatment, guided by the expertise of Amir T. Fathi MD. In the dynamic landscape of 2023, Dr. Fathi’s insights illuminate the remarkable progress being made, specifically within the realm of IDH 1/2-mutant AML cases. This transformative approach integrates cutting-edge molecular insights and targeted therapies, revolutionizing the trajectory of AML care. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL…

Harry Paul Erba, MD Professor of Medicine Member of the Duke Cancer Institute This content features Harry Paul Erba, MD, who discusses the optimization of frontline therapy for FLT3 mutated AML patients, focusing on quizartinib’s impact. Dr. Erba explains the pivotal role of FLT3 receptor tyrosine kinase in hematopoiesis and its connection to AML blast. He details the variations in FLT3 mutations, encompassing internal tandem duplication (ITD) and TKD mutations, elucidating their distinct prognostic implications. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU…

Joseph D. Khoury, MD is the Stokes-Shackleford Professor and Chair, Department of Pathology and Microbiology, University of Nebraska Medical Center. In a dynamic presentation at the recent event, Joseph D. Khoury, MD delved into the intricate realm of Acute Myeloid Leukemia (AML), shedding light on genetic advancements, diagnostic nuances, and promising targeted therapies. The engaging discourse began with gratitude for the invitation and San Diego’s delightful weather. Coming from varied backgrounds like Houston, Texas, and even Nebraska, the speaker emphasized their unique vantage point straddling different locales. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online…

The “MOASC SPOTLIGHT ON ONCOLOGY – GU ASCO UPDATES” seminar, led by Dr. Nataliya Mar, Clinical Associate Professor in the Division of Hematology/Oncology at the University of California Irvine, August 12, 2023 This discussion marked a significant milestone in the field of genitourinary oncology. Dr. Mar’s insightful presentation delved into various scenarios, revealing the complex landscape of oncology care and the advancements in treatment strategies. At the outset, Dr. Mar disclosed her affiliations with leading pharmaceutical companies, including Seattle Genetics, Aveo, Eisai, Tempus, and Merck, which underscores the relevance of her insights and findings in the context of emerging therapies…

Pancreatic Cancer Updates – Insights from Vincent Chung, MDDiscover the latest advancements in the field of pancreatic cancer through an enlightening presentation by Dr. Vincent Chung, a distinguished figure in oncology and a consultant for Perthera. Delve into the comprehensive exploration of Pancreatic Cancer, its challenges, and the transformative approaches to treatment. This event, held on August 12, 2023, at the MOASC / UCI Spotlight on Oncology, presents crucial updates that could revolutionize the landscape of pancreatic cancer care.Understanding the Scope of the ProblemWith the unfortunate distinction of having the worst survival rates among solid tumors, pancreatic cancer poses a…

Anthony El-Khoueiry, MD. As the Associate Director for Clinical Research and Phase 1 Program Director at the prestigious USC Norris Comprehensive Cancer Center Discover the latest advancements in the field of Hepatobiliary Cancers in this comprehensive session titled “Hepatobiliary Cancers Therapeutic Updates” featuring the esteemed Anthony El-Khoueiry, MD. As the Associate Director for Clinical Research and Phase 1 Program Director at the prestigious USC Norris Comprehensive Cancer Center, Dr. El-Khoueiry brings his expertise to illuminate the cutting-edge developments in the treatment of hepatobiliary cancers.This session delves into critical topics that are reshaping the landscape of hepatobiliary cancer therapies. The intricate…

MOASC – Spotlight on Oncology Colorectal Cancer AbstractsDate: August 12, 2023Location: Huntington Beach, CAPresenter: Jason A. Zell, DO, MPHPosition: Professor, Vice Chief of Academic AffairsDivision of Hematology/Oncology, Dept. of MedicineUniversity of California Irvine In this spotlight session on oncology, the focus was on Colorectal Cancer (CRC) abstracts, with special attention given to the latest advancements and research findings. The presenter, Dr. Jason A. Zell, a distinguished figure in the field, holds the position of Professor and Vice Chief of Academic Affairs within the Division of Hematology/Oncology at the University of California Irvine. Abstracts were presented, shedding light on significant studies…

Dr. Sayeh Lavasani, MD, MSc, FRCPC, an Associate Clinical Professor in the Division of Hematology Oncology at the Department of Medicine, UCI Health, presented updates on breast cancer research during the MOASC (Medical Oncology Association of Southern California) Spotlight On Oncology. Here’s a breakdown of the key topics discussed: Presenter Disclosures: Dr. Lavasani’s disclosures include associations with Daichii Sankyo, Seagen, Sermonix, and Astrazeneca for honorarium, institutional research funding, consultation, and speaker engagements. Outline: Hormone Positive Breast Cancer: Early Stage (NATALEE) Metastatic Breast Cancer: SONIA HER2+ Breast Cancer: PHERGain (Cortes et al.) Key Highlights: Hormone Positive Breast Cancer – NATALEE Study:…

In the ever-evolving world of oncology, there is always a beacon of hope on the horizon. The latest such promise comes in the form of a drug known as Sacituzumab Govitecan. This compound, while complex in name, is pioneering some of the latest advancements in cancer treatments, particularly in the realm of Triple-Negative Breast Cancer (TNBC). What is Sacituzumab Govitecan? Every drug, from the over-the-counter solutions to groundbreaking cancer treatments, has a story to tell, often starting with its name. Sacituzumab Govitecan isn’t merely a jumble of syllables. It’s a name derived from the drug’s intricate nature and function. While…

Sanam Loghavi is Assistant Professor, Department of Hematopathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX Sanam Loghavi is an accomplished pathologist known for her expertise in the field of hematopathology and her contributions to the diagnosis and understanding of various hematologic malignancies, including acute myeloid leukemia (AML). Her work focuses on unraveling the molecular intricacies of AML and other blood disorders to enhance patient care through personalized treatment strategies. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open -…

For those with an interest in the management of acute myeloid leukemia, the conference provided a unique and valuable platform. Attendees commended the insightful talks and the lively debates that ensued, offering a wealth of perspectives and research ideas. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com The sentiment expressed was overwhelmingly positive, with participants applauding the conference’s exceptional speakers, engaged audience, interactive format, and the prospect of forging new…

The discussion revolves around the complexities of Blinatumomab treatment for leukemia, with experts debating the reasons behind the partial clinical hold on cooperative group studies, concerns about combining treatments concurrently, and the potential impact of reducing chemotherapy intensity. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Topics also include the risk of CNS relapses, the significance of IT chemotherapy, and the emergence of CD19-negative relapses with Blinatumomab. The experts emphasize…

The panel discussed various aspects related to the use of next-generation sequencing (NGS) and flow cytometry for minimal residual disease (MRD) detection in patients with various types of leukemia, particularly acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). They touched upon the challenges and benefits of using NGS for detecting MRD at greater detection depths. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com The question arose as to whether…

In this lively debate, experts engage in a comprehensive analysis of Nelarabine’s efficacy in the treatment of ALL. The discussion covers its benefits and drawbacks, particularly focusing on its usage in EFS and DFS within the pivotal trial. Controversial points emerge regarding its impact on survival rates, with contrasting viewpoints on its effectiveness in pediatric and adult populations. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com The potential of combination…

In a dynamic and insightful debate, leading experts in the field of leukemia treatment delved into the intricacies of optimizing therapies for relapsed acute lymphoblastic leukemia (ALL). The discussion revolved around cost-effective strategies and clinical considerations for achieving enhanced outcomes. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com The experts examined the potential of combining various treatments, including CAR T-cell therapy, to mitigate the escalating costs of managing relapsed ALL.…

We mourn the profound loss of Dr. Krystal Cascetta, a committed oncologist and breast cancer researcher. Our hearts extend to her family, friends, patients, and colleagues in these challenging times. In memory of her life and contributions, we highlight the severe mental health challenges faced by oncology professionals. Managing gravely ill patients, navigating intricate diseases, and daily confrontations with mortality exert a heavy emotional burden. Oncologists face higher rates of burnout, depression, and suicide compared to other physicians. It’s crucial that we foster a culture in oncology that forefronts mental health and well-being. Dr. Cascetta was not only a compassionate…

The panel discussion centered on the optimization of leukemia treatment, particularly focusing on the combination of venetoclax with various therapies. Preclinical data and pathophysiology were explored, highlighting the potential of inhibiting JAK2 mutations with venetoclax. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Concerns were raised about CNS relapse and CD19-negative relapses, emphasizing the need for continued IT chemotherapy. The balance between systemic chemotherapy reduction and comprehensive coverage with antigen-directed…

When discussing the myriad of cancers that affect humans, head and neck cancers, though slightly less talked about, remain a significant concern for medical professionals and patients alike. These cancers, which can originate in the oral cavity, throat, larynx, paranasal sinuses, and nasal cavity, are often diagnosed late due to their subtle initial symptoms. As a result, the need for effective treatments is palpable, especially for those cases where the disease has metastasized or recurred after initial treatment. Over the years, there’s been a growing interest in leveraging the body’s immune system to combat cancers, a treatment approach referred to…

The discussion centered on optimizing leukemia treatment strategies through the combination of immunotherapies and chemotherapy. The concern of CNS relapse and CD19-negative relapses was highlighted, emphasizing the importance of continued IT chemotherapy. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com While there is interest in reducing systemic chemotherapy, caution was advised due to potential resistance. The potential of combining antigen-directed therapies with chemotherapy for better coverage was discussed, along with…

This in-depth discussion among experts explores various facets of leukemia management. The conversation spans topics including challenges in clonotypable patients, the significance of MRD negativity in high-risk genetics, and the ongoing debate surrounding the necessity of transplantation for specific patient groups. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com The experts also touch on practical considerations, such as the frequency of peripheral blood monitoring compared to bone marrow assessments.

Medical experts engaged in a discussion about advancing pediatric acute myeloid leukemia (AML) treatment strategies. Venetoclax, a promising drug, was a focal point, and its potential inclusion in pediatric protocols was explored. The challenge of adapting adult regimens to pediatric patients while considering drug forms suitable for children was discussed. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com The importance of collaborative trials, merging efforts across pediatric and adult AML,…

Navigating the ever-evolving landscape of leukemia treatment has become an intricate endeavor, with recent clinical trials offering intriguing insights and sparking lively debates. These trials delve into the effectiveness of innovative therapies such as gilteritinib and midostaurin, potentially reshaping the foundation of standard care protocols. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Controversies emerge surrounding the significance of randomized studies in a rapidly changing environment, where salvage therapies like…

The conversation focuses on AML treatments, including arsenic and another frontline approach. Preventing relapses through non-toxic drugs like masitinib is explored. Financial obstacles and customized treatments are discussed. The importance of precise timing for treatments is highlighted. Myelosuppression and new dosing ideas are brought up. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Clinical trial design’s role in optimizing treatment is mentioned, with examples of challenges in drug approval. The need…

In this discussion, the focus is on optimizing Acute Myeloid Leukemia (AML) treatment. The idea of reducing drug doses upon achieving remission is challenged, questioning its efficacy against resistant disease. The notion of increasing drug doses to target resistance for improved outcomes is proposed. Perspectives diverge, with one side highlighting the need for conservative dosing to manage toxicities, while the other suggests early, aggressive intervention. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus…

Leading experts engage in a comprehensive discussion on the intricate landscape of long-term remission and resistance patterns in transplanted acute myeloid leukemia (AML) patients, focusing on the potential role of Menin Inhibitor maintenance therapy. The dialogue delves into post-transplant outcomes and the emergence of resistance mutations, referencing previous presentations at the American Society of Hematology (ASH) meeting. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Central topics include the distinction…

Ryan Fitzpatrick, CEO, MD Education In opening the Focus Meeting 2023, Ryan Fitzpatrick, CEO, expresses gratitude to attendees and collaborators for their efforts. The importance of gathered speakers is emphasized, promising insightful discussions. Professional conduct and the value of fellows and junior faculty members are underscored. Logistical details, including breaks and a dinner, are outlined. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Online resources’ availability is noted, extending the…

The discussion revolves around complex topics related to acute myeloid leukemia (AML), including its groups, molecular markers, patient eligibility for clinical trials, and considerations of germline predisposition. Participants delve into the challenges of defining AML subtypes, the significance of molecular markers in diagnosis and treatment decisions, and the potential impact of germline factors on patient outcomes. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com The conversation also touches on the…

In the ever-evolving landscape of medical science, melanoma and Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN) have remained two of the most formidable cancers to treat. Both of these cancers present unique challenges due to their aggressive nature and high recurrence rate. Yet, in the shadow of these challenges, targeted therapies have emerged as a beacon of hope. Targeted therapies are a relatively new addition to the oncological toolkit. Unlike traditional treatments that indiscriminately target both healthy and cancerous cells, targeted therapies focus precisely on the specific genes and proteins that are involved in the growth…

Joseph D. Khoury, MD is the Stokes-Shackleford Professor and Chair, Department of Pathology and Microbiology, University of Nebraska Medical Center. Joseph Corey, MD, Chair of Pathology and Microbiology at the University of Nebraska Medical Center, Omaha, presented a seminar on acute myeloid leukemia (AML) classification and its genetic underpinnings. The conference offered a platform for AML physicians and diagnostic specialists, like Corey, to exchange insights. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus…

Harry Paul Erba, MD Professor of Medicine and Member of the Duke Cancer Institute Harry Erba, MD, a respected Duke University Medicine Professor, refines intensive chemotherapy for FLT3 mutated AML patients. He validates Midostaurin’s potential via the RATIFY trial and now focuses on potent second-gen FLT3 inhibitors. In the quantum first study, quizartinib enhances ITD mutated AML survival, particularly in younger patients (hazard ratio 0.68). Older patients also benefit, though less significantly (hazard ratio 0.9). REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU…

Amir Fathi, MD Associate Professor of Medicine, Harvard Medical School Program Director, Center for Leukemia- Massachusetts General Hospital. Amir Fathi MD, an esteemed professional at Massachusetts General Hospital in Boston, Massachusetts, recently delivered a noteworthy presentation at a conference. His talk centered on induction strategies within the realm of patients lacking FLT3 mutations, showcasing the breadth of his expertise. The event proved to be a platform for various experts, including Amir’s colleagues, who shared compelling data. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration…

Alexander Edward Perl, MD, MS is a member of the leukemia program in the Abramson Cancer Center of the University of Pennsylvania and an Associate Professor of Medicine at the Perelman School of Medicine. Alexander E. Perl, MD, MS, an associate professor in the leukemia program at the Abrams Cancer Center, University of Pennsylvania, recently presented at a conference. He discussed identifying resistance mechanisms in FLT3 mutated AML patients and shared data-driven strategies for improved treatment. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/…